301 results on '"S. Parisi"'
Search Results
2. P522: ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY
- Author
-
G. Cristiano, J. Nanni, L. Zannoni, C. Sartor, S. Parisi, S. Paolini, C. Papayannidis, M. Cavo, and A. Curti
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
3. The Italian Society for Rheumatology recommendations for the management of axial spondyloarthritis
- Author
-
M. Manara, I. Prevete, A. Marchesoni, S. D'Angelo, A. Cauli, A. Zanetti, A. Ariani, A. Bortoluzzi, S. Parisi, C.A. Scirè, and N. Ughi
- Subjects
Clinical Practice Guideline ,axial spondyloarthritis ,management ,treatment. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Over the last few years, the landscape of treatments for axial spondyloarthritis (SpA) has been rapidly evolving, urging international scientific societies to draft or update existing clinical practice guidelines (CPGs) on the management of axial SpA. The Italian Society for Rheumatology (SIR) committed to provide revised and adapted evidence- and expert-based recommendations for the management of patients with axial SpA in Italy. A systematic approach to the adaptation of existing CPGs - the ADAPTE methodology - was adopted to obtain updated recommendations suitable for the Italian context. A systematic literature search was performed in Medline and Embase databases to find international CPGs and consensus statements with recommendations for the management of axial SpA published in the previous five years. A working group composed of rheumatologists with proven experience in the management of axial SpA and methodologists identified the key research questions which guided study selection and data extraction. Guideline quality was assessed using the Appraisal of Guidelines Research and Evaluation (AGREE) II tool. The Italian recommendations were developed by endorsing or adapting and rewording some existing recommendations. The draft of the recommendations was sent to a multidisciplinary group of external reviewers for comment and rating. Six original CPGs were selected and used to create this SIR CPG, which includes a final set of 14 recommendations covering the management of patients with axial SpA across the following domains: assessment, pharmacological and non-pharmacological treatment, and follow-up. The dissemination and implementation of these SIR recommendations are expected to support an evidencebased clinical approach to the management of patients with axial SpA in Italy.
- Published
- 2021
- Full Text
- View/download PDF
4. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia. Best practices based on current scientific evidence
- Author
-
A. Ariani, L. Bazzichi, P. Sarzi-Puttini, F. Salaffi, M. Manara, I. Prevete, A. Bortoluzzi, G. Carrara, C.A. Scirè, N. Ughi, and S. Parisi
- Subjects
Clinical Practice Guideline ,recommendations ,fibromyalgia ,diagnosis ,treatment. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Fibromyalgia or fibromyalgia syndrome (FMS) is defined as a central sensitization syndrome characterized by the dysfunction of neurocircuits detecting, transmitting and processing nociceptive stimuli; the prevalent manifestation is musculoskeletal pain. In addition to pain, there are multiple accompanying symptoms, in common with other algo-dysfunctional syndromes, which are reflected in a broad spectrum of somatic, neurocognitive and neuro-vegetative manifestations. An evidence-based approach is essential in FMS management, in order to improve patient health and to reduce its social burden. Since in the last ten years new international guidelines for clinical practice (Clinical Practice Guidelines or CPGs) concerning FMS diagnosis and pharmacological/ non-pharmacological management have been published, the Italian Society of Rheumatology (SIR) has decided to adapt them to the Italian national setting. The framework of the Guidelines International Network Adaptation Working Group was adopted to identify, appraise (AGREE II), synthesize, and customize the most recent CPGs on FMS to the needs of the Italian healthcare context. A working group of rheumatologists from SIR epidemiology unit and FMS experts identified relevant clinical questions to guide the systematic review of the literature. The target audience of these CPGs included physicians and healthcare professionals who manage FMS. The adapted recommendations were finally assessed by an external multidisciplinary panel. From the systematic search in databases (Pubmed/Medline, Embase) and grey literature, 6 CPGs were selected and appraised by two independent raters. The combination of the scientific evidence underlying the original CPGs with expert opinion lead to the development of 17 recommendations. The quality of evidence for each recommendation was reported and their potential impact on clinical practice was assessed. These SIR recommendations are expected to be a valuable aid in the diagnosis and treatment of FMS, as they will contribute to disseminate the best practice on the basis of the current scientific evidence.
- Published
- 2021
- Full Text
- View/download PDF
5. Breast reconstruction and radiation therapy: consensus statements of the Italian association of radiotherapy and clinical oncology (AIRO) breast cancer group
- Author
-
I. Meattini, N. Rocco, M. Bernini, E. Bonzano, F. De Rose, M.C. De Santis, P. Franco, B. Meduri, S. Parisi, N. Pasinetti, A. Prisco, A. Fontana, C. Becherini, and L. Livi
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2021
- Full Text
- View/download PDF
6. Reply to the Letter to the Editor: The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica
- Author
-
N. Ughi, G.D. Sebastiani, R. Gerli, C. Salvarani, S. Parisi, A. Ariani, I. Prevete, M. Manara, F. Rumi, C.A. Scirè, and A. Bortoluzzi
- Subjects
Medicine ,Internal medicine ,RC31-1245 - Abstract
Not available
- Published
- 2020
- Full Text
- View/download PDF
7. The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica
- Author
-
N. Ughi, G.D. Sebastiani, R. Gerli, C. Salvarani, S. Parisi, A. Ariani, I. Prevete, M. Manara, F. Rumi, C.A. Sciré, and A. Bortoluzzi
- Subjects
Clinical Practice Guideline ,recommendations ,polymyalgia rheumatica ,management ,treatment. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Objective: to provide evidence-based up-to-date recommendations for the management of patients with a definite diagnosis of polymyalgia rheumatica (PMR). Methods: A systematic literature review was performed to find the existing clinical practice guidelines (CPGs) on PMR and the framework of the Guidelines International Network Adaptation Working Group was used to appraise (AGREE II), synthesize, and customize the recommendations according to the needs of the Italian healthcare context. Rheumatologists on behalf of the Italian Society of Rheumatology (SIR) and from the SIR Epidemiology Unit joined the working group and identified the key health questions on PMR to guide the systematic literature review. Physicians, including general practitioners and specialists, and health professionals who manage PMR in the clinical practice were the target audience. The final recommendations were rated externally by a multi-disciplinary and multi-professional group of stakeholders. Results: From the systematic search in databases (Medline, Embase) and grey literature, 3 CPGs were identified and appraised by two independent raters. Combining the statements and the evidence from these CPGs, 9 recommendations were developed by endorsement or adaptation in response to the initial key health questions. The quality of evidence was graded and the working group discussed the final recommendations in view of their implementation in the Italian healthcare context. Conclusions: In absence of national guidelines so far, these recommendations are the first to provide guidance for the management of patients with a diagnosis of PMR in Italy and they are expected to ensure the best evidence-based clinical practice for this disease.
- Published
- 2020
- Full Text
- View/download PDF
8. The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis
- Author
-
S. Parisi, A. Bortoluzzi, G.D. Sebastiani, F. Conti, R. Caporali, N. Ughi, I. Prevete, A. Ariani, M. Manara, G. Carrara, and C.A. Scirè
- Subjects
Clinical practice guidelines ,recommendations ,rheumatoid arthritis ,management ,safety. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder characterised by chronic joint inflammation, leading to functional disability and increased risk of premature death. Clinical practice guidelines (CPGs) are expected to play a key role in improving management of RA, across the different phases of the disease course. Since new evidence has become available, the Italian Society for Rheumatology (SIR) has been prompted to update the 2011 recommendations on management of RA. The framework of the Guidelines International Network Adaptation Working Group was adopted to identify, appraise (AGREE II), synthesize, and customize the existing RA CPGs to the Italian healthcare context. The task force consisting of rheumatologists from the SIR Epidemiology Research Unit and a committee with experience in RA identified key health questions to guide a systematic literature review. The target audience includes physicians and health professionals who manage RA in practice, and the target population includes adult patients diagnosed as having RA. An external multi-disciplinary committee rated the final version of the CPGs. From the systematic search in databases (Medline, Embase) and grey literature, 6 CPGs were selected and appraised by two independent raters. Combining evidence and statements from these CPGs and clinical expertise, 8 (Management) +6 (Safety) recommendations were developed and graded according to the level of evidence. The statements and potential impact on clinical practice were discussed and assessed. These revised recommendations are intended to provide guidance for the management of RA and to disseminate the best evidence-based clinical practices for this disease.
- Published
- 2019
- Full Text
- View/download PDF
9. Providing updated guidelines for the management of rheumatic diseases in Italy with the ADAPTE methodology: a project by the Italian Society for Rheumatology
- Author
-
M. Manara, N. Ughi, A. Ariani, A. Bortoluzzi, S. Parisi, I. Prevete, G. Carrara, A. Zanetti, F. Rumi, and C.A. Scirè
- Subjects
Medicine ,Internal medicine ,RC31-1245 - Abstract
Not available
- Published
- 2019
- Full Text
- View/download PDF
10. The Italian Society of Rheumatology clinical practice guidelines for the diagnosis and management of gout
- Author
-
N. Ughi, I. Prevete, R. Ramonda, L. Cavagna, G. Filippou, M. Manara, A. Bortoluzzi, S. Parisi, A. Ariani, and C.A. Scirè
- Subjects
Clinical practice guideline ,recommendations ,gout ,diagnosis ,treatment. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Gout is a chronic disease with an increased risk of premature death related to comorbidities. Treatment of gout has proved suboptimal and clinical practice guidelines (CPGs) are expected to have a key role in achieving improvement. Since new evidence has become available, the Italian Society for Rheumatology (SIR) has been prompted to update the 2013 recommendations on the diagnosis and management of gout. The framework of the Guidelines International Network Adaptation Working Group was adopted to identify, appraise (AGREE II), synthesize, and customize the existing gout CPGs to the needs of the Italian healthcare context. The task force consisting of rheumatologists from the SIR Epidemiology Unit and a committee with experience on gout identified key health questions to guide a systematic literature review. The target audience includes physicians and health professionals who manage gout in practice, and the target population includes adult patients suspected or diagnosed as having gout. These recommendations were finally rated by an external multi-disciplinary commission. From a systematic search in databases (Medline, Embase) and grey literature, 8 CPGs were selected and appraised by two independent raters. Combining evidence and statements from these CPGs and clinical expertise, 14 recommendations were developed and graded according to the level of evidence. The statements and potential impact on clinical practice were discussed and assessed. These revised recommendations are intended to provide guidance for the diagnosis and the treatment of gout and to disseminate the best evidence-based healthcare for this disease.
- Published
- 2019
- Full Text
- View/download PDF
11. The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of knee, hip and hand osteoarthritis
- Author
-
A. Ariani, M. Manara, A. Fioravanti, F. Iannone, F. Salaffi, N. Ughi, I. Prevete, A. Bortoluzzi, S. Parisi, and C.A. Scirè
- Subjects
Clinical practice guidelines ,recommendations ,osteoarthritis ,diagnosis ,treatment. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
Osteoarthritis (OA) is the most common musculoskeletal disease leading to functional decline and loss in quality of life. Knees, hands and hips are frequently affected joints with a relevant clinical and socio-economic burden. An evidence-based approach to OA management is essential in order to improve patients’ health and to decrease social burdens. Since new international clinical practice guidelines (CPGs) focused on diagnosis or pharmacological/non-pharmacological treatment have become available in the last ten years, the Italian Society for Rheumatology (SIR) was prompted to revise and customize them for a multidisciplinary audience of specialists involved in the management of OA. The framework of the Guidelines International Network Adaptation Working Group was adopted to identify, appraise (AGREE II), synthesize, and customize the existing CPGs on OA to the needs of the Italian healthcare context. The task force, consisting of rheumatologists from the SIR epidemiology research unit and a committee with experience of OA, identified key health questions to guide a systematic review of published guidelines. The target audience included physicians and health professionals who manage OA. An external panel of stakeholders rated the guidelines. From a systematic search in databases (Pubmed/Medline, Embase) and grey literature, 11 CPGs were selected and appraised by two independent raters. Combining evidence and statements from these CPGs and clinical expertise, 16 guidelines were developed and graded according to the level of evidence. Agreement and potential impact on clinical practice were assessed. These revised guidelines are intended to provide guidance for diagnosis and treatment of OA and to disseminate best evidence-based strategies management of the disease.
- Published
- 2019
- Full Text
- View/download PDF
12. Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids
- Author
-
S. Parisi, M. Bruzzone, C. Centanaro Di Vittorio, A. Laganà, C.L. Peroni, and E. Fusaro
- Subjects
Systemic sclerosis, Raynaud’s phenomenon, Endothelin receptor antagonist, Bosentan, Raynaud’s condition score. ,Medicine ,Internal medicine ,RC31-1245 - Abstract
The objective of this study was to evaluate the efficacy of the endothelin receptor antagonist, bosentan, in patients with Raynaud’s phenomenon secondary to systemic sclerosis never treated with prostanoids and without digital ulcers. The study design is a preliminary, prospective open label trial. The patients recruited took one 62.5 mg dose of bosentan twice daily for 4 weeks, followed by 125 mg twice daily for 24 weeks. Of the 10 patients recruited, all completed the study. The reduction in Raynaud’s phenomenon attacks at week 24 from the baseline was statistically significant (Δ-1.3, P=0.0126). The Raynaud’s condition score showed a statistically significant improvement (Δ-1.4, P=0.0279), as did the visual analog pain scale (Δ-1.5, P=0.0016) at the 24th week. Bosentan appears to be effective and may be a valid alternative for the treatment of severe secondary Raynaud’s phenomenon for patients where prostanoids therapy is contraindicated or refused.
- Published
- 2014
- Full Text
- View/download PDF
13. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative
- Author
-
Torsten Zuberbier, Amir Abdul Latiff, Xenofon Aggelidis, Matthias Augustin, Radu‐Gheorghe Balan, Christine Bangert, Lisa Beck, Thomas Bieber, Jonathan A. Bernstein, Marta Bertolin Colilla, Alejandro Berardi, Anna Bedbrook, Carsten Bindslev‐Jensen, Jean Bousquet, Marjolein deBruin‐Weller, Dayanne Bruscky, Betul Buyuktiryaki, Giorgio Walter Canonica, Carla Castro, Natia Chanturidze, Herberto Jose Chong‐Neto, Chia‐Yu Chu, Leena Chularojanamontri, Michael Cork, Roberta F. J. Criado, Laia Curto Barredo, Adnan Custovic, Ulf Darsow, Arben Emurlai, Ana dePablo, Stefano DelGiacco, Giampiero Girolomoni, Tanja Deleva Jovanova, Mette Deleuran, Nikolaos Douladiris, Bruno Duarte, Ruta Dubakiene, Esben Eller, Batya Engel‐Yeger, Luis Felipe Ensina, Nelson Rosario Filho, Carsten Flohr, Daria Fomina, Wojciech Francuzik, Maria Laura Galimberti, Ana M. Giménez‐Arnau, Kiran Godse, Charlotte Gotthard Mortz, Maia Gotua, Michihiro Hide, Wolfram Hoetzenecker, Nicolas Hunzelmann, Alan Irvine, Carolyn Jack, Ioanna Kanavarou, Norito Katoh, Tamar Kinaciyan, Emek Kocatürk, Kanokvalai Kulthanan, Hilde Lapeere, Susanne Lau, Mariana Machado Forti Nastri, Michael Makris, Eli Mansour, Alexander Marsland, Mara Morelo Rocha Felix, Ana Paula Moschione Castro, Eustachio Nettis, J. F. Nicolas, Audrey Nosbaum, Mikaela Odemyr, Niki Papapostolou, Claudio A. S. Parisi, Sushil Paudel, Jonny Peter, Prakash Pokharel, Luis Puig, Tamara Quint, German Dario Ramon, Frederico Regateiro, Giampaolo Ricci, Cristine Rosario, Cansin Sackesen, Peter Schmid‐Grendelmeier, Esther Serra‐Baldrich, Kristina Siemens, Cathrine Smith, Petra Staubach, Katarina Stevanovic, Özlem Su‐Kücük, Gordon Sussman, Simona Tavecchio, Natasa Teovska Mitrevska, Diamant Thaci, Elias Toubi, Claudia Traidl‐Hoffmann, Regina Treudler, Zahava Vadasz, Ingrid vanHofman, Maria Teresa Ventura, Zhao Wang, Thomas Werfel, Andreas Wollenberg, Ariana Yang, Yik Weng Yew, Zuotao Zhao, Ricardo Zwiener, and Margitta Worm
- Subjects
atopic dermatitis ,eczema ,guidance ,ICP ,integrated care pathways ,multidisciplinary ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Abstract Introduction The integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems. Methods The GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres. Results The AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD. Conclusion The AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.
- Published
- 2023
- Full Text
- View/download PDF
14. Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases
- Author
-
Andrea Duminuco, Calogero Vetro, Cinzia Maugeri, Elisa Mauro, Giuseppe A. M. Palumbo, Marina S. Parisi, Benedetta Esposito, Giuseppe Giuliano, Alessandra Romano, and Francesco Di Raimondo
- Subjects
Saprochaete capitata ,immunocompromised patients ,voriconazole ,hematological malignancies ,emergent and multiresistant micro-organisms ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Infections occurring in immunocompromised patients after intensive chemotherapy are often difficult to eradicate and are capable of even being fatal. New emergent and dangerous drug-resistant micro-organisms are likely to appear in these specific scenarios. Clinical features mainly include progressive pneumonia, bacteriemia/fungemia, or extrapulmonary dissemination among infections. The treatment of these microorganisms is still an open challenge since there is a lack of clear treatment guidelines. Indeed, infections from these microorganisms can lead to a rapidly fatal clinical course in immunocompromised patients, especially those who have acute leukemia. We describe the case of a young patient with acute myeloid leukemia who contracted an infection from Saprochaete capitata during post-chemotherapy aplasia.
- Published
- 2022
- Full Text
- View/download PDF
15. Consenso argentino de diagnóstico y tratamiento del angioedema hereditario
- Author
-
Daniel O. Vázquez, Dario O. Josviak, Claudio A. Fantini, Natalia L. Fili, Alejandro M. Berardi, Ricardo D. Zwiener, René A. Baillieau, Gonzalo F. Chorzepa, Gabriel O. Fueyo, Claudia M. Garcia, Gabriel Gattolin, Monica B. Marocco, Claudio A. S. Parisi, Marcelo D. Strass, and Jose E. Fabiani
- Subjects
angioedema hereditario ,Argentina ,consenso ,diagnóstico ,tratamiento ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Objetivos: El angioedema hereditario es una enfermedad poco frecuente. Durante los últimos años se han desarrollado muchas investigaciones y registrado avances con el objetivo de entender mejor la fisiopatología y optimizar la atención a los pacientes. Diversos grupos de trabajo internacionales han intentado clarificar y normalizar el cuidado de pacientes con angioedema hereditario, lo que se ha reflejado en guías y consensos. Consideramos necesario desarrollar un documento de consenso con recomendaciones para el diagnóstico y tratamiento del angioedema hereditario en Argentina. Metodología: Un grupo de expertos de Argentina, conformado por especialistas en Alergia e Inmunología mediante metodología de ronda de encuestas a distancia y reuniones presenciales llevó adelante la elaboración del consenso pretendido. Resultados: Se establecieron recomendaciones basadas en la evidencia publicada y en el criterio de los expertos participantes. Las recomendaciones se enfocaron en el diagnóstico, tratamiento y profilaxis de las crisis a corto y largo plazo, control de situaciones especiales y consideraciones del sistema de salud en Argentina. Conclusión: Las recomendaciones establecidas en este consenso permitirán optimizar la atención médica de los pacientes con angioedema hereditario en Argentina.
- Published
- 2021
- Full Text
- View/download PDF
16. Capillary penetration for the development of a method for the assessment of shelf-life of foods
- Author
-
D. Georgiou, E. P. Kalogianni, G. Dimitreli, E. Ftouli, and S. Parisi
- Subjects
General Chemical Engineering ,Safety, Risk, Reliability and Quality ,Industrial and Manufacturing Engineering ,Food Science - Abstract
Temperature sensitive foods require monitoring of their time–temperature history in order to assure their safety and high quality. The same holds for other perishable products such as medical and pharmaceutical. The best means to have information on the time–temperature history of a product is by having measurement of these variables along the whole product shelf-life. As an answer to this need several time–temperature indicators have been developed and commercialized for monitoring the quality of food products. In this work a full history time–temperature indicator (TTI) has been designed and developed based on capillary penetration of safe and low surface tension liquids in micro porous polyethylene porous media. For the development of the indicator the appropriate porous media and penetration liquids were selected and capillary penetration of the selected liquids took place at two different temperatures. Based on the results of the capillary penetration experiments the TTI was developed and a prototype was evaluated in a food product in order to assess its capability to be used in food packaging. The results showed that the TTI is simple in use and could provide a quantitative and easy-to-read response. Moreover, the response of the TTI could be calibrated by changing several design parameters, in order to match the quality deterioration kinetics of the specific food product to be monitored.
- Published
- 2022
17. Prevalence of atopic dermatitis in adults☆
- Author
-
Claudio A S Parisi, Maria V. Angles, Estefania Juszkiewicz Franze, Luis Daniel Mazzuoccolo, Carolina Antonietti, and Ana Clara Torre
- Subjects
Adult ,medicine.medical_specialty ,business.industry ,Eczema ,Dermatology ,Atopic dermatitis ,medicine.disease ,Dermatitis, Atopic ,Cross-Sectional Studies ,Research Letter ,Prevalence ,Medicine ,Humans ,business - Published
- 2021
18. Prolonged iatrogenic thoracic duct chylous fistula in neck surgery: conservative management or surgery? A literature review
- Author
-
Claudio Gambardella, R. Ruggiero, S. Parisi, Luigi Brusciano, D Parmeggiani, L. Docimo, G Terracciano, Giorgia Gualtieri, Parmeggiani, D, Gualtieri, G, Terracciano, G, Gambardella, C, Parisi, S, Brusciano, L, Ruggiero, R, and Docimo, L
- Subjects
medicine.medical_specialty ,Fistula ,Conservative management ,business.industry ,Bile duct ligation ,Incidence (epidemiology) ,Iatrogenic Disease ,Chylous fistula ,Conservative Treatment ,Thoracic duct ,Malignant disease ,Thoracic Duct ,Surgery ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine ,Humans ,030223 otorhinolaryngology ,Complication ,business - Abstract
Background: Thoracic duct chylous fistula is a rare complication following neck surgery, especially for malignant disease. Despite its low incidence, it can be a life-threatening postoperative complication increasing the risk of infection, bleeding, hypovolemia, electrolyte imbalance, and malnutrition. Currently, the management of thoracic duct fistula is not standardized yet. It can range from conservative to surgical approaches, and even when surgery indication occurs, there is no unanimous agreement on timing and operative steps, so the surgical approach still remains mostly subjective, in accordance with clinical conditions of the patients and with surgeon’s experience. Aims: The aim of the study was to search into Literature a common accepted behaviour in thoracic duct chylous fistula occurring. Methods: A literature review was carried out. Conservative treatments include fasting associated with total parental nutrition or low-fat diet, compressive dressings, and octreotide administration. If conservative treatment fails, in order to avoid dangerous consequences, functional repair of the thoracic duct injury with lymphovenous microanastomosis should be the preferred solution, rather than an approach that obliterates the thoracic duct or lymphatic–chylous pathways, such as thoracic duct embolization, therapeutic lymphangiography, and thoracic duct ligation. Conclusions: In our experience, patients undergone thyroidectomy and neck dissection for thyroid-differentiated cancer, who report an unrecognized thoracic duct chylous fistula after surgery, must be treated via integrated conservative and surgical treatment. A literature review about thoracic duct chylous fistula following neck surgery, focusing on the current management and therapeutic approach, was furthermore carried out, in order to delineate the actual therapeutic options in case of thoracic duct chylous fistula occurrence.
- Published
- 2021
19. 1369P Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients
- Author
-
G. Francolini, B. Detti, V. Di Cataldo, S. Caini, A.R. Alitto, null S. Parisi, C. Demofonti, A. Bruni, G. Ingrosso, G. Timon, A.G. Allegra, L. Burchini, V. Salvestrini, G. Frosini, C. Cerbai, L. Visani, C. Becherini, I. Desideri, I. Meattini, and L. Livi
- Subjects
Oncology ,Hematology - Published
- 2022
20. A method to improve the color rendering accuracy in cultural heritage: preliminary results
- Author
-
D Allegra, G Furnari, S Gargano, A Gueli, S Parisi, S Pasquale, F Stanco, and G Stella
- Subjects
History ,ComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISION ,Computer Science Applications ,Education - Abstract
Color specification is an important challenge in many application domains including Cultural Heritage. The collection of metadata concerning Cultural Heritage involves the valorization, fruition and becomes part of the conservation process. It becomes essential to find methods that simplify and optimize the acquisition of such data as color information. In this regard, in this work we present the preliminary results of a project that involves the acquisition by 3D scanner of samples of different colors placed in a controlled environment and with different illumination conditions. To make more accurate the color rendering, the color coordinates of each sample were measured by a spectrophotometer. All the obtained measurements become part of a dataset with which to train a machine learning model that learns how to perform the transformation from the RGB to the CIELab color space in different lighting condition.
- Published
- 2022
21. Tratamiento de la rinitis alérgica en pediatría en Argentina. Documento de actualización
- Author
-
R. Maximiliano Gomez, Pablo Moreno, Marcela García, Jorge César Martínez, Juan Croce, Juan Carlos Ivancevich, Claudio A S Parisi, Daniel Vázquez, and Cora Isabel Onetti
- Subjects
Pediatrics ,medicine.medical_specialty ,Allergy ,Pharmacological therapy ,medicine.diagnostic_test ,business.industry ,Specific immunotherapy ,Inhaled corticosteroids ,Physical examination ,Disease ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,030228 respiratory system ,030225 pediatrics ,medicine ,Immunology and Allergy ,Differential diagnosis ,business ,Pediatric population - Abstract
La rinitis alérgica (RA) es la enfermedad alérgica más frecuente. La prevalencia en niños y adolescentes de Argentina oscila entre 22.3 y 34.9 %. Ante esto, integrantes de los comités científicos de pediatría y rinitis de la Asociación Argentina de Alergia e Inmunología Clínica (AAAeIC) revisaron evidencia científica para actualizar las normativas terapéuticas de esta patología en la población pediátrica. La clasificación y categorización de la RA se encuentra actualmente en plena revisión en todo el orbe. Es necesario realizar un diagnóstico diferencial con otras rinitis no alérgicas en los niños, y confirmar la RA con base en la historia clínica, el examen físico, la determinación de biomarcadores o pruebas cutáneas. El tratamiento no farmacológico incluye la educación y pautas de control ambiental para alérgenos como ácaros, hongos anemófilos, epitelio de animales y pólenes. Se propone un tratamiento farmacológico escalonado de acuerdo con el control de la enfermedad. Los antihistamínicos de segunda generación no sedativos son la primera línea de tratamiento. La asociación con descongestivos orales no se recomienda en menores de cuatro años. Los corticoides nasales inhalados son de primera elección en formas moderadas y graves. El presente documento alerta a los pediatras sobre la importancia del diagnóstico precoz, el uso racional del tratamiento farmacológico escalonado y la inmunoterapia específica en niños.
- Published
- 2020
22. Profilaxis en Angioedema Hereditario con C1 inhibidor normal
- Author
-
Claudio A S Parisi, Mercedes Parrales Villacreses, Pablo Pérez Martínez, Ariela Gonzalez, and Dina Glocer
- Subjects
medicine.medical_specialty ,Allergy ,biology ,business.industry ,Genetic disorder ,medicine.disease ,Dermatology ,C1-inhibitor ,Minor trauma ,TOOTH EXTRACTIONS ,Hereditary angioedema ,medicine ,biology.protein ,Immunology and Allergy ,In patient ,Genetic diagnosis ,business - Abstract
Antecedentes: El Angioedema Hereditario es una enfermedad genética rara; se manifiesta principalmente con edema cutáneo y/o mucoso. Pequeños traumas pueden desencadenar eventos potencialmente fatales. En Angioedema Hereditario tipo I y tipo II, se puede hacer profilaxis a corto plazo con concentrado plasmático de C1 Inhibidor. En Angioedema Hereditario con C1 Inhibidor normal, la profilaxis aún no está estandarizada pero este podría ser beneficioso. Reporte de caso: Mujer de 69 años, con diagnóstico genético de angioedema hereditario con C1 inhibidor normal, consultó a la Sección de Alergia por requerir exodoncias dentarias múltiples. El procedimiento se realizó bajo anestesia general, utilizándose como profilaxis 1000U de concentrado de C1 inhibidor derivado del plasma una hora antes. Cursó el postoperatorio en terapia intensiva con buena evolución. Conclusiones: Resaltamos la posibilidad de utilizar con éxito el concentrado de C1 inhibidor derivado del plasma como profilaxis, en pacientes con Angioedema Hereditario con C1 inhibidor normal.
- Published
- 2021
23. P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD)
- Author
-
B. Garibaldi, M. Franciosa, F. Pilo, D. Menotti, V. Cardinali, L. Brunetti, E. A. Martino, E. Vigna, I. Tanasi, A. Duminuco, C. Maugeri, M. S. Parisi, P. F. Fiumara, E. Mauro, M. Gentile, M. P. Martelli, D. Capelli, C. Romani, S. Galimberti, G. A. Palumbo, F. Di Raimondo, and C. Vetro
- Subjects
Hematology - Published
- 2022
24. [Argentine Consensus of the Diagnosis and Treatment of Hereditary Angioedema]
- Author
-
Daniel O, Vazquez, Darío O, Josviack, Claudio A, Fantini, Natalia L, Fili, Alejandro M, Berardi, Ricardo D, Zwiener, René A, Baillieau, Gonzalo F, Chorzepa, Gabriel O, Fueyo, Claudia M, García, Gabriel, Gattolin, Mónica B, Marocco, Claudio A S, Parisi, Marcelo D, Strass, and José E, Fabiani
- Subjects
Pregnancy ,Surveys and Questionnaires ,Angioedemas, Hereditary ,Argentina ,Humans ,Female ,Child ,Algorithms - Abstract
Hereditary angioedema (HAE) is a rare disease. During the last years, many studies and advances have been developed with the aim of better understanding the pathophysiology, as well as optimizing patient management. Several international working groups have attempted to clarify and standardize the care of HAE communicated as guidelines and consensus recommendations. We considered necessary to provide recommendations for the diagnosis and treatment of patients with HAE in Argentina.A group of specialists of allergy and immunology from Argentina by using the online surveys methodology as well as face to face meetings developed the intended consensus.Recommendations were established based on published evidence and the expert opinion. The consensus focused on diagnosis, acute management of attacks, short and long-term prophylaxis, special situations (pediatrics and pregnancy) and disease management considering the health care system in Argentina.The recommendations established in this consensus guidelines will optimize the management of patients with HAE in Argentina.Objetivos: El angioedema hereditario es una enfermedad poco frecuente. Durante los últimos años se han desarrollado muchas investigaciones y registrado avances con el objetivo de entender mejor la fisiopatología y optimizar la atención a los pacientes. Diversos grupos de trabajo internacionales han intentado clarificar y normalizar el cuidado de pacientes con angioedema hereditario, lo que se ha reflejado en guías y consensos. Consideramos necesario desarrollar un documento de consenso con recomendaciones para el diagnóstico y tratamiento del angioedema hereditario en Argentina. Metodología: Un grupo de expertos de Argentina, conformado por especialistas en Alergia e Inmunología mediante metodología de ronda de encuestas a distancia y reuniones presenciales llevó adelante la elaboración del consenso pretendido. Resultados: Se establecieron recomendaciones basadas en la evidencia publicada y en el criterio de los expertos participantes. Las recomendaciones se enfocaron en el diagnóstico, tratamiento y profilaxis de las crisis a corto y largo plazo, control de situaciones especiales y consideraciones del sistema de salud en Argentina. Conclusión: Las recomendaciones establecidas en este consenso permitirán optimizar la atención médica de los pacientes con angioedema hereditario en Argentina.
- Published
- 2021
25. Update on latex allergy: New insights into an old problem
- Author
-
Claudio A S Parisi, Maria Beatrice Bilò, Kevin J. Kelly, Maria Chiara Braschi, Natalhie Acuña-Ortega, Alejandra Macías-Weinmann, Hae-Sim Park, Mario Sánchez-Borges, Sandra Nora González-Díaz, Ignacio J. Ansotegui, Anahí Yáñez, Victoria Cardona, Mario A. Piga, Institut Català de la Salut, [Parisi CAS] Pediatric and Adult Allergy Sections, Hospital Italiano de Buenos Aires, Argentina. [Kelly KJ] University of North Carolina - Chapel Hill, North Carolina, USA. [Ansotegui IJ] Department of Allergy & Immunology, Hospital Quironsalud Bizkaia, Bilbao, Spain. [Gonzalez-Díaz SN] Regional Center of Allergy and Clinical Immunology, Hospital Universitario 'Dr. José Eleuterio González' y Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico. [Bilò MB] Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy. Allergy Unit - Department of Internal Medicine, University Hospital of Ancona, Italy. [Cardona V] Secció d’Al•lèrgia, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Pulmonary and Respiratory Medicine ,vigilancia en salud ambiental::vigilancia de la salud del trabajador::salud laboral::vigilancia del ambiente de trabajo::riesgos profesionales::exposición profesional [VIGILANCIA SANITARIA] ,medicine.medical_specialty ,Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores] ,profesiones sanitarias::medicina::salud global [DISCIPLINAS Y OCUPACIONES] ,Latex ,Immunology ,Developing country ,Wordwide ,Disease ,Article ,Riscos per a la salut - Avaluació ,Other subheadings::Other subheadings::/prevention & control [Other subheadings] ,Environmental health ,enfermedades del sistema inmune::hipersensibilidad::hipersensibilidad al látex [ENFERMEDADES] ,Epidemiology ,Health care ,medicine ,Global health ,Immunology and Allergy ,IgE mediated hypersensitivity ,Al·lèrgia al làtex ,Salut mundial ,business.industry ,RC581-607 ,medicine.disease ,Management ,Latex allergy ,Environmental Health Surveillance::Surveillance of the Workers Health::Occupational Health::Surveillance of Working Environment::Occupational Risks::Occupational Exposure [HEALTH SURVEILLANCE] ,Immunologic diseases. Allergy ,business ,Developed country ,Working environment ,Immune System Diseases::Hypersensitivity::Latex Hypersensitivity [DISEASES] ,Health Occupations::Medicine::Global Health [DISCIPLINES AND OCCUPATIONS] - Abstract
Làtex; Gestió; A nivell mundial Latex; Management; Wordwide Látex; Gestión; A nivel mundial Despite the efforts made to mitigate the consequences of this disease, natural rubber latex allergy (NRLA) continues to be a global health problem and is still considered one of the main worries in the working environment in many countries throughout the world. Due to thousands of products containing latex, it is not surprising that the current statistics suggest that prevalence remains high among healthcare workers and susceptible patients. In developed countries, reduction in the prevalence of IgE-mediated allergy to latex proteins from gloves may lead to lax attention by health care personnel. On the other hand, this situation is different in developing countries where there is a lack of epidemiological data associated with a deficit in education and awareness of this issue. The aim of this review is to provide an update of the current knowledge and practical recommendations regarding NRLA by allergologists from different parts of the world with experience in this field. The authors have not received any funding to prepare the manuscript.
- Published
- 2021
26. Algunos desafíos en mucopolisacaridosis tipo I
- Author
-
Graciela Zuccaro, Hernán Eiroa, Hernan Amartino, Mariana Cazalas, Claudia Arberas, Adriana Berretta, Claudio A S Parisi, Guillermo Drelichman, Marcela Pereyra, Carmen De Cunto, Luisa Bay, Adriana Copiz, Alberto Maffey, Hugo Botto, Alejandro Fainboim, Virginia Fano, Graciela Espada, Andrea Schenone, Norberto Guelber, Alejandra Antacle, Rodrigo Remondino, Raquel Staciuk, and Norma Spécola
- Subjects
0301 basic medicine ,Allergy ,Pediatrics ,medicine.medical_specialty ,business.industry ,Eye disease ,Adult care ,Enzyme replacement therapy ,medicine.disease ,03 medical and health sciences ,Mucopolysaccharidosis type I ,030104 developmental biology ,0302 clinical medicine ,Pediatrics, Perinatology and Child Health ,medicine ,business ,030217 neurology & neurosurgery - Abstract
Here we describe the current challenges of mucopolysaccharidosis type I: the need for an adequate classification, establishing its relationship to therapeutic indications; an early diagnosis, from neonatal screening, its advantages and barriers, to clinical suspicion of severe and attenuated forms; spinal and eye disease care, from diagnosis to follow-up and treatment; allergic reactions caused by enzyme replacement therapy, their diagnosis and treatment. And lastly, transition to adult care.
- Published
- 2021
27. New recommendations for the care of patients with mucopolysaccharidosis type I
- Author
-
Hernán Eiroa, Hugo Botto, Alberto Maffey, Carmen De Cunto, Raquel Staciuk, Mariana Cazalas, Graciela Espada, Claudia Arberas, Adriana Copiz, Andrea Schenone, Rodrigo Remondino, Rorberto Guelber, Graciela Zuccaro, Norma Spécola, Alejandro Fainboim, Virginia Fano, Claudio A S Parisi, Marcela Pereyra, Alejandra Antacle, Guillermo Drelichman, Hernan Amartino, Adriana Berretta, and Luisa Bay
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Consensus ,medicine.diagnostic_test ,business.industry ,Mucopolysaccharidosis I ,Argentina ,03 medical and health sciences ,Mucopolysaccharidosis type I ,030104 developmental biology ,0302 clinical medicine ,Pediatrics, Perinatology and Child Health ,medicine ,Humans ,Airway ,Intensive care medicine ,business ,030217 neurology & neurosurgery ,Genetic testing - Abstract
Considering the advances made on mucopolysaccharidosis type I after the consensus study published by a group of experts in Argentina in 2008, recommendations about genetic testing, cardiological follow-up, airway care, hearing impairment detection, spinal and neurological conditions, as well as current treatments, were reviewed. Emphasis was placed on the need for early diagnosis and treatment, as well as an interdisciplinary follow-up.Dados los avances sobre mucopolisacaridosis I con posterioridad al consenso publicado en la Argentina por un grupo de expertos en 2008, se revisan recomendaciones respecto a estudios genéticos, seguimiento cardiológico, cuidado de la vía aérea, alertas sobre aspectos auditivos, de la patología espinal y neurológica. Se hace revisión de la terapéutica actual y se enfatiza en la necesidad de un diagnóstico y tratamiento precoces, así como de un seguimiento interdisciplinario.
- Published
- 2021
28. Cross-sectional survey about the prevalence of allergic rhinitis in Argentina: Study PARA
- Author
-
Gabriel Gattolin, Iris V Medina, Georgina Logusso, Claudio A S Parisi, Daniel Vázquez, and Sergio Arias
- Subjects
lcsh:Immunologic diseases. Allergy ,Adult ,Male ,medicine.medical_specialty ,Allergy ,Adolescent ,Cross-sectional study ,Population ,Argentina ,Nasal congestion ,self-reported questionnaire ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,children ,Epidemiology ,adults ,Prevalence ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Medical diagnosis ,Family history ,Child ,education ,education.field_of_study ,allergic rhinitis ,High prevalence ,business.industry ,Urban Health ,medicine.disease ,Rhinitis, Allergic ,Cross-Sectional Studies ,030228 respiratory system ,Child, Preschool ,epidemiology ,Female ,Self Report ,medicine.symptom ,lcsh:RC581-607 ,business ,Demography - Abstract
There are very few studies about the prevalence of allergic rhinitis in Argentina.To determine the prevalence of allergic rhinitis in a population of inhabitants between the ages of 5 and 44 in Argentina.A cross-sectional national study in which a self-reported questionnaire was used. The included participants are between the ages of 5 and 44 and they reside in urban areas. The information was collected by phone.3200 participants were surveyed: 51.8% were women, 37.6% were between the ages of 5 and 19, and 62.4%, were between the ages of 20 and 44. The global prevalence of symptoms of allergic rhinitis was of 20.5%; the most frequent symptoms were sneezing (58.5%) and nasal congestion (51.4%). Overall, 44.3% of the participants had a family history of allergies. Allergic rhinitis was more frequent in women; the prevalence was of 22.3% in the group of participants between the ages of 5 and 19, and of 19.4% in the group of participants between the ages of 20 and 40 (p=0.0545); 63.8% of participants with symptoms did not have a medical diagnosis.The results of this first cross-sectional national survey have confirmed the high prevalence of self-reported symptoms of allergic rhinitis in adults and children in Argentina, particularly in women.Antecedentes: Existen pocos estudios sobre la prevalencia de rinitis alérgica en Argentina. Objetivo: Determinar la prevalencia de rinitis alérgica en una población entre cinco y 44 años de edad en Argentina. Métodos: Estudio transversal nacional en el que se utilizó un cuestionario autoinformado. Se incluyeron participantes entre cinco y 44 años de edad residentes en áreas urbanas. La información se recolectó telefónicamente. Resultados: Se encuestaron 3200 participantes: 51.8 % del sexo femenino, 37.6 % tenía entre cinco y 19 años y 62.4 % entre 20 y 44 años. La prevalencia global de síntomas de rinitis alérgica fue de 20.5 %; los síntomas más frecuentes fueron los estornudos (58.5 %) y la congestión nasal (51.4 %). En general, 44.3 % de los participantes tenía antecedentes familiares de alergia. La rinitis alérgica fue más frecuente en las mujeres; la prevalencia fue de 22.3 % en el grupo de cinco a 19 años y de 19.4 % en el de 20 a 44 años (p = 0.0545); 63.8 % de los participantes con síntomas no tenía diagnóstico médico. Conclusiones: Los resultados de esta primera encuesta transversal nacional confirman la alta prevalencia de síntomas autoinformados de rinitis alérgica en adultos y niños en Argentina, especialmente en las mujeres.
- Published
- 2019
29. Epidemiology and prevention of respiratory syncytial virus infections in children in Italy
- Author
-
Elena Bozzola, Paolo Bonanni, Fabio Mosca, Alessandra Coscia, S Parisi, Paolo Manzoni, Giovanni Checcucci Lisi, Fabrizio Sandri, Teresa Mazzone, Marcello Lanari, Giorgio Piacentini, Chiara Azzari, Eugenio Baraldi, Azzari C., Baraldi E., Bonanni P., Bozzola E., Coscia A., Lanari M., Manzoni P., Mazzone T., Sandri F., Checcucci Lisi G., Parisi S., Piacentini G., and Mosca F.
- Subjects
Pediatrics ,medicine.medical_specialty ,RSV vaccines ,First year of life ,Respiratory Syncytial Virus Infections ,Review ,Respiratory syncytial virus ,Antiviral Agents ,Virus ,RJ1-570 ,RSV prevention ,RSV vaccine ,Epidemiology ,medicine ,Bronchiolitis, Viral ,Humans ,Viral ,Respiratory system ,Asthma ,Cause of death ,Palivizumab ,Antiviral Agent ,RSV pediatric burden ,Monoclonal antibodie ,business.industry ,Infant, Newborn ,LRTI ,Monoclonal antibodies ,RSV ,RSV epidemiology ,Gestational age ,Infant ,medicine.disease ,Newborn ,Italy ,Bronchiolitis ,Respiratory syncytial viru ,Population Surveillance ,business ,Human - Abstract
Respiratory syncytial virus (RSV) is the leading global cause of respiratory infections in infants and the second most frequent cause of death during the first year of life. This highly contagious seasonal virus is responsible for approximately 3 million hospitalizations and 120,000 deaths annually among children under the age of 5 years. Bronchiolitis is the most common severe manifestation; however, RSV infections are associated with an increased long-term risk for recurring wheezing and the development of asthma. There is an unmet need for new agents and a universal strategy to prevent RSV infections starting at the time of birth. RSV is active between November and April in Italy, and prevention strategies must ensure that all neonates and infants under 1 year of age are protected during the endemic season, regardless of gestational age at birth and timing of birth relative to the epidemic season. Approaches under development include maternal vaccines to protect neonates during their first months, monoclonal antibodies to provide immediate protection lasting up to 5 months, and pediatric vaccines for longer-lasting protection. Meanwhile, improvements are needed in infection surveillance and reporting to improve case identification and better characterize seasonal trends in infections along the Italian peninsula. Rapid diagnostic tests and confirmatory laboratory testing should be used for the differential diagnosis of respiratory pathogens in children. Stakeholders and policymakers must develop access pathways once new agents are available to reduce the burden of infections and hospitalizations.
- Published
- 2021
30. Use of Hexyon/Hexacima/Hexaxim in preterm infants in Europe
- Author
-
B Isnardy, L Ralfkiaer, N Badzhinerov, P Dhont, K Krogh, M Puchilita, M Kolenc, S Parisi, F Caracci, and F Boisnard
- Subjects
Public Health, Environmental and Occupational Health - Abstract
Background Worldwide 13 million babies born prematurely every year have increased susceptibility to infection and require adequate immunization. Hexavalent vaccines against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B and Haemophilus influenzae type b are standard of care in pediatric vaccination and are particularly important for preterm infants. Hexyon® is registered in Europe since April 2013. Methods Considering birth data from official national databases and only countries with periods of exclusive use of Hexyon from 2013-19, we estimated the total number of preterm infants ( Results Since registration, Hexyon has been used in 23 European countries and exclusively used in the following: Austria, Feb-2017 to present; Belgium, Jul-2014 (Flanders)/Sep-2015 (Overall) to present; Bulgaria, Nov-2014 to Dec-2016; Croatia, Jan-2016 to present; Denmark, Feb-2016 to Apr-2017; Italy, Apr-2016 to present, exclusivity based on Regions; Macedonia, Oct-2015 to present; Norway, Feb-2017 to present; Romania, Apr-2015 to Dec-2017. The estimated total number of preterm infants during these periods of exclusive use is 183 000. Assuming 90% vaccination coverage, ∼164 700 preterm infants received at least 1 dose of this vaccine. From the analysis of the post-marketing safety data available to date, no new risk has been identified in preterm infants. Conclusions Hexyon has become a standard for hexavalent immunization in infants, regardless of the gestational age at birth. More than 90 million doses have been administered worldwide, including the estimated 164 000 preterm infants in the 9 European countries considered here. The EU Marketing Authorization granted in 2013 with no contraindication for use in preterm infants, was renewed in 2018 and the black triangle was removed confirming that the safety of Hexyon is well established. The marketing authorization holder continues to support evidence generation for use in preterm infants. Key messages Hexyon/Hexacima/Hexaxim has become a standard for hexavalent immunization in infants including for preterm infants (
- Published
- 2020
31. Definition, aims, and implementation of GA [sup] 2 LEN/HAEi Angioedema Centers of Reference and Excellence
- Author
-
Kemal Özyurt, Teresa Caballero, Aharon Kessel, Andrew J. MacGinnitie, Solange Oliveira Rodrigues Valle, Anthony J. Castaldo, Markus Magerl, Regis A. Campos, Adam Reich, Heike Röckmann-Helmbach, R. Y. Meshkova, Mario Sánchez-Borges, Richard G. Gower, Anna Zalewska-Janowska, Daria Fomina, Célia Costa, Allen P. Kaplan, Marc A. Riedl, Naoko Inomata, Avner Reshef, Alejandro Malbrán, Aurélie Du-Thanh, N. Prior, Hilary Longhurst, Margarida Gonçalo, Kiran Godse, Rosana Câmara Agondi, Andreas Kleinheinz, Inmaculada Martinez-Saguer, Mona Al-Ahmad, Thilo Jakob, Luis Felipe Ensina, José Ignacio Larco Sousa, Anna Tagka, Chikako Nishigori, Nicola Wagner, Hye Ryun Kang, Michael Makris, Nicholas Brodszki, Ricardo Dario Zwiener, Jan Nicolay, Alicja Kasperska-Zając, Iris V Medina, Ignacio J. Ansotegui, Marcin Stobiecki, Alejandro Berardi, Danny M. Cohn, Claudio A S Parisi, Angèle Soria, Torsten Zuberbier, Dario O. Josviack, E Serra-Baldrich, Jonathan A. Bernstein, Anette Bygum, Isao Ohsawa, Henriette Farkas, Iman Nasr, Thomas Buttgereit, Jonathan Peter, Carsten Bindslev-Jensen, Paulo Ricardo Criado, Wolfgang Pfützner, Natalia Fili, Silvia Mariel Ferrucci, Petra Staubach, Peter Schmid-Grendelmeier, M. Gotua, Marcus Maurer, Jose Fabiani, Gordon Sussman, A. Marsland, Konrad Bork, Andrea Zanichelli, Simon Francis Thomsen, Isabelle Boccon-Gibod, Mauro Cancian, German D. Ramon, Zuotao Zhao, Nikolaos G. Papadopoulos, Martijn B. A. van Doorn, Andrea Bauer, Kanokvalai Kulthanan, Claudio Fantini, Henrik Balle Boysen, Lilian Varga, Dorota Krasowska, Ana Giménez-Arnau, Werner Aberer, Ivan Cherrez-Ojeda, Roberta F. Criado, Constance H. Katelaris, Martin Metz, Riccardo Asero, Mitja Košnik, Stephen Betschel, M Sendhil Kumaran, Sigurd Broesby-Olsen, Moshe Ben-Shoshan, Rand Arnaout, Regina Treudler, Laurence Bouillet, Natalia Ilina, Maryam Ali Al-Nesf, Emek Kocatürk, Emel Aygören-Pürsün, William R. Lumry, Guillermo Guidos-Fogelbach, Yuxiang Zhi, Mark Gompels, Andac Salman, Christina Weber-Chrysochoou, Michihiro Hide, Young Min Ye, Aslı Gelincik, William B Smith, Timothy J. Craig, Bruce Ritchie, Daniel O. Vázquez, Mojca Bizjak, Atsushi Fukunaga, Ragıp Ertaş, Urs C. Steiner, Faradiba Sarquis Serpa, Farrukh R. Sheikh, Michael Rudenko, Paula J. Busse, Luisa Karla de Paula Arruda, Liangchun Wang, Todor A. Popov, Anete Sevciovic Grumach, Joachim Dissemond, Dorottya Csuka, Ignasi Figueras-Nart, Aleena Banerji, Tıp Fakültesi, Kemal Özyurt / 0000-0002-6913-8310, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Dermatology, Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219), Maurer, Marcus, Werner, Aberer, Agondi, Rosana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Ansotegui, Ignacio, Arnaout, Rand, Arruda, Luisa Karla, Asero, Riccardo, Aygoeren-Puersue, Emel, Banerji, Aleena, Bauer, Andrea, Ben-Shoshan, Moshe, Berardi, Alejandro, Bernstein, Jonathan A, Betschel, Stephen, Bindslev-Jensen, Carsten, Bizjak, Mojca, Boccon-Gibod, Isabelle, Bork, Konrad, Bouillet, Laurence, Boysen, Henrik Balle, Brodszki, Nicholas, Broesby-Olsen, Sigurd, Busse, Paula, Buttgereit, Thomas, Bygum, Anette, Caballero, Teresa, Campos, Regis A., Cancian, Mauro, Cherrez-Ojeda, Ivan, Cohn, Danny M., Costa, Celia, Craig, Timothy, Criado, Paulo Ricardo, Criado, Roberta F., Csuka, Dorottya, Dissemond, Joachim, Du-Thanh, Aurelie, Ensina, Luis Felipe, Ertaş, Ragıp, Fabiani, Jose E., Fantini, Claudio, Farkas, Henriette, Ferrucci, Silvia Mariel, Figueras-Nart, Ignasi, Fili, Natalia L., Fomina, Daria, Fukunaga, Atsushi, Gelincik, Aslı, Gimenez-Arnau, Ana, Godse, Kiran, Gompels, Mark, Goncalo, Margarida, Gotua, Maia, Gower, Richard, Grumach, Anete S, Guidos-Fogelbach, Guillermo, Hide, Michihiro, Ilina, Natalia, Inomata, Naoko, Jakob, Thilo, Josviack, Dario O., Kang, Hye-Ryun, Kaplan, Allen, Kasperska-Zajac, Alicja, Katelaris, Constance, Kessel, Aharon, Kleinheinz, Andreas, Kosnik, Mitja, Krasowska, Dorota, Kulthanan, Kanokvalai, Kumaran, M. Sendhil, Larco Sousa, Jose Ignacio, Longhurst, Hilary J., Lumry, William, MacGinnitie, Andrew, Magerl, Markus, Makris, Michael P., Malbran, Alejandro, Marsland, Alexander, Martinez-Saguer, Inmaculada, Medina, Iris V., Meshkova, Raisa, Metz, Martin, Nasr, Iman, Nicolay, Jan, Nishigori, Chikako V., Nishigori, Chikako, Ohsawa, Isao, Özyurt, Kemal, Papadopoulos, Nikolaos G., Parisi, Claudio A. S., Peter, Jonathan Grant, Pfuetzner, Wolfgang, Popov, Todor, Prior, Nieves, Ramon, German D., Reich, Adam, Reshef, Avner, Riedl, Marc A., Ritchie, Bruce, Rockmann-Helmbach, Heike, Rudenko, Michael, Salman, Andaç, Sanchez-Borges, Mario, Schmid-Grendelmeier, Peter, Serpa, Faradiba S., Serra-Baldrich, Esther, Sheikh, Farrukh R., Smith, William, Soria, Angele, Staubach, Petra, Steiner, Urs C., Stobiecki, Marcin, Sussman, Gordon, Tagka, Anna, Thomsen, Simon Francis, Treudler, Regina, Valle, Solange, van Doorn, Martijn, Varga, Lilian, Vazquez, Daniel O., Wagner, Nicola, Wang, Liangchun, Weber-Chrysochoou, Christina, Ye, Young-Min, Zalewska-Janowska, Anna, Zanichelli, Andrea, Zhao, Zuotao, Zhi, Yuxiang, Zuberbier, Torsten, Zwiener, Ricardo D., Castaldo, Anthony, and School of Medicine
- Subjects
medicine.medical_specialty ,Edema angioneuròtic ,Urticaria ,media_common.quotation_subject ,Immunology ,education ,GA2LEN ,Angioedema ,Center ,Excellence ,Management ,urticaria ,centres of reference and excelence ,immune system diseases ,center ,medicine ,Immunology and Allergy ,Center (algebra and category theory) ,Angioneurotic edema ,skin and connective tissue diseases ,media_common ,udc:616.1 ,business.industry ,angioedema ,humanities ,referenčni centri odličnosti ,Medicine ,Allergy ,Family medicine ,excellence ,medicine.symptom ,business ,Global Allergy and Asthma European Network ,Urticària ,management - Abstract
This document summarizes the aims of GA2 LEN/HAEi Angioedema Centers of Reference and Excellence (ACAREs) and elaborates the requirements that ACAREs must fulfill to become certified. It also provides (see Appendix S1) background information on GA2LEN and HAEi, including HAEi member organizations and regional patient advocates, on why we need an Angioedema Center of Reference and Excellence (ACARE) program and network, and on the accreditation and certification process, governance and funding, and on the interaction with other GA2LEN networks of centers of reference and excellence. The protocols, aims, requirements, and provisions related to becoming a certified CARE are based on (a) the experience of the GA2LEN UCARE network and (b) input from angioedema patients, general practitioners, and angioedema specialists.
- Published
- 2020
32. Assainissement non collectif en France : synthèse du suiviin situdes installations réalisé de 2011 à 2016
- Author
-
S. Parisi, B. Mouline, L. Dubourg, C. Boutin, N. Portier, L. Souliac, D. Dhumeaux, P. Artuit, C. Leval, V. Dubois, L. Olivier, C. Szabo, S. Jousse, A. Decout, P. Branchu, Réduire, valoriser, réutiliser les ressources des eaux résiduaires (UR REVERSAAL), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Centre d'Etudes et d'Expertise sur les Risques, l'Environnement, la Mobilité et l'Aménagement (Cerema), CONSEIL DEPARTEMENTAL DE LA MAYENNE FRA, Partenaires IRSTEA, Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA)-Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), SPANC DE LA REGION DE SAINT JACUT LES PINS MORBIHAN FRA, CHARENTRE EAUX FRA, ASSOCIATION DES MAIRES RURAUX DE FRANCE FRA, Agence de l'eau Rhône Méditérranée Corse, Agence Française pour la Biodiversité (AFB), SATESE DU CONSEIL DEPARTEMENTAL DU CALVADOS FRA, COMMUNAUTE D'AGGLOMERATION DE L'OUEST RHODANIEN RHONE FRA, MINISTERE DE LA TRANSITION ECOLOGIQUE ET SOLIDAIRE FRA, and Agence de l'Eau Loire-Bretagne
- Subjects
TREATED WASTEWATE ,DESCRIPTIVE STATISTICS ,0207 environmental engineering ,Ocean Engineering ,STATISTIQUES DESCRIPTIVES ,02 engineering and technology ,LOGIQUE FLOUE ,FUZZY LOGIC ,010501 environmental sciences ,01 natural sciences ,12. Responsible consumption ,ON-SITE SANITATION ,020701 environmental engineering ,0105 earth and related environmental sciences ,Water Science and Technology ,Fluid Flow and Transfer Processes ,ASSAINISSEMENT NON COLLECTIF ,EAUX USÉES TRAITÉES ,6. Clean water ,SUIVI IN SITU ,13. Climate action ,[SDE]Environmental Sciences ,IN SITU ASSESSMENT ,ENTRETIEN CURATIF ,CURATIVE MAINTENANCE ,General Agricultural and Biological Sciences - Abstract
International audience; An assessment of 1 286 validated data from 231 on-site sanitation facilities was carried during 6 years in France. Facilities are classified in 3 families, 13 categories and 33 systems according to sanitation processes and industrial technologies developed by manufacturer. Classes of treated wastewater quality were created based on the analysis of the French regulation used for wastewater treatment. The frequency of curative maintenance is analyzed using fuzzy logic. Then, these two criteria are jointly analyzed and allow assessing 18 systems out of 33. Authors, members of the national public group "assessment of on-site sanitation systems", provide objective information on the quality of treated wastewater and curative maintenance of twenty systems under real operating conditions. Systems that obtain an "acceptable" quality class for both treated wastewater quality and frequency of curative maintenance are all from the Biofilm Systems on Fine Media (BSFM) family: i) traditional sand filter (S1) and 2 approved systems: ii) constructed wetland system (CW) and iii) one system of the coconut shavings category (CS2). Hence, only 12% of approved systems studied in this project are "acceptable" for both treated wastewater quality and frequency of curative maintenance. This study gives scientific and technical information for political stakeholders at different territory scales: Municipality, Public entities in charge of the on-site sanitation service (Spanc), French departments, Water agencies, Ministry in charge of on-site wastewater treatment and European Commission.; Le suivi in situ des installations d'assainissement non collectif (ANC) a duré 6 ans et a permis de collecter 1286 données validées sur 231 installations. Les installations sont classées en 3 familles, 13 filières et 33 dispositifs selon des critères liés aux processus d'épuration et aux techniques industrielles développées par les fabricants. Des classes de qualité des eaux usées traitées ont été élaborées, à partir de l'analyse de la réglementation française technique appliquée au traitement des eaux usées. La fréquence d'entretien curatif des installations est analysée par un outil utilisant la logique floue. Ces deux critères sont ensuite analysés conjointement et permettent de qualifier 18 des 33 dispositifs évalués. Les auteurs, constitués en groupe national public « suivi in situ des installations d'assainissement non collectif », fournissent ainsi des informations objectives d'une vingtaine de dispositifs d'ANC dans leurs conditions réelles de fonctionnement. Les dispositifs qui obtiennent une classe de qualité « acceptable » à la fois pour la qualité des eaux usées traitées et la fréquence d'entretien curatif sont trois dispositifs de la famille CFSF : i) le filtre à sable traditionnel de la filière « sable » (S1) ; deux dispositifs agréés : ii) le dispositif étudié de la filière « végétaux » (FPR) et iii) l'un des deux dispositifs étudiés de la filière « copeaux de coco » (CC2). Ainsi, seulement 12 % des dispositifs agréés étudiés répondent au qualificatif « acceptable » à la fois vis-à-vis de la qualité des eaux usées traitées et de la fréquence d'entretien curatif. Cette étude donne un éclairage scientifique et technique destiné à alimenter la réflexion des responsables des politiques publiques aux diverses échelles du territoire : Commune, Collectivité en charge du service public d'assainissement non collectif (SPANC), Conseil Départemental, Agences de bassin, Ministères en charge de l'assainissement non collectif et Commission Européenne.
- Published
- 2018
33. Impact of the COVID-19 outbreak on an Italian cohort of systemic sclerosis patients
- Author
-
Raffaella Landi, Eleonora Rizzi, C Realmuto, M Parodi, Mattia Bellan, A Finucci, P Rossi, Giuseppe Francesco Casciaro, Filippo Patrucco, P.P. Sainaghi, Mario Pirisi, Anita R. Pedrinelli, Micol Giulia Cittone, M C Ditto, Cristina Rigamonti, M Todoerti, Veronica Vassia, P Stobbione, S Parisi, and E Fusaro
- Subjects
Male ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,viruses ,Immunology ,Scleroderma ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Rheumatology ,Adrenal Cortex Hormones ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,030212 general & internal medicine ,Respiratory system ,Ulcer ,Retrospective Studies ,030203 arthritis & rheumatology ,Pulmonary Arterial Hypertension ,Scleroderma, Systemic ,SARS-CoV-2 ,business.industry ,Oxygen Inhalation Therapy ,COVID-19 ,virus diseases ,Outbreak ,Raynaud Disease ,Retrospective cohort study ,Hydroxychloroquine ,General Medicine ,Middle Aged ,medicine.disease ,Telemedicine ,Telephone ,Italy ,Antirheumatic Agents ,Cohort ,Female ,Lung Diseases, Interstitial ,business ,medicine.drug ,Cohort study - Abstract
The outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, causing coronavirus disease 2019 (COVID-19), has had a deleterious effect on the delivery of care for all acu...
- Published
- 2020
34. Very similar ultrasound images and very different histological diagnosis: A case report
- Author
-
A.P. Carus, S. Parisi, E. Viora, C. Zavattero, A. Puppo, and R. Giacchello
- Subjects
medicine.medical_specialty ,Radiological and Ultrasound Technology ,business.industry ,Abstracts from the Fourth International IOTA Congress ,Histological diagnosis ,Ultrasound ,medicine ,Radiology, Nuclear Medicine and imaging ,Radiology ,business - Published
- 2019
35. Diagnostic confirmation of amoxicillin allergy in children treated at the Division of Pediatric Allergy
- Author
-
Alfredo Eymann, Natalia Petriz, Claudio A S Parisi, and Christian Morelo Torres
- Subjects
Pediatrics ,medicine.medical_specialty ,Allergy ,education.field_of_study ,business.industry ,medicine.drug_class ,Antibiotics ,Population ,Retrospective cohort study ,medicine.disease ,Confidence interval ,Amoxicillin allergy ,Pediatrics, Perinatology and Child Health ,Epidemiology ,medicine ,Pediatric allergy ,business ,education - Abstract
Amoxicillin is a beta-lactam antibiotic commonly indicated in pediatrics and the most frequent cause of drug allergies.To determine the proportion of confirmed amoxicillin allergy in children with diagnostic suspicion seen at the Division of Pediatric Allergy.This descriptive, retrospective study was done between January 2009 and January 2017 in children younger than 18 years with diagnostic suspicion of amoxicillin allergy. The diagnosis was based on questions and specific tests.A total of 234 patients were included; amoxicillin allergy was diagnosed in 10.7 % (95 % confidence interval: 7-15). These patients had a higher prevalence of immediate symptoms (40 % vs. 22 %,Amoxicillin allergy in children referred to specialists was confirmed in 10.7 %.La amoxicilina es un antibiótico betalactámico comúnmente indicado en pediatría y es la causa más frecuente de alergia a medicamentos. Objetivos: Determinar la proporción de alergia confirmada a amoxicilina en niños con sospecha diagnóstica, atendidos en una sección de alergia pediátrica. Población y métodos: Estudio descriptivo retrospectivo entre enero de 2009 y enero de 2017, en menores de 18 años con sospecha diagnóstica de alergia a amoxicilina. Se realizó el diagnóstico según interrogatorio y pruebas específicas. Resultados: Fueron incluidos 234 pacientes; se diagnosticó alergia a la amoxicilina en el 10,7 % (intervalo de confianza del 95 %: 7-15). Estos pacientes tenían mayor prevalencia de síntomas inmediatos (el 40 % vs. el 22 %, p = 0,048) y de exposición previa a betalactámicos (el 84 % vs. el 56 %, p = 0,007). Conclusión: La confirmación de alergia a la amoxicilina en niños derivados a especialistas fue del 10,7 %.
- Published
- 2019
36. 1369P Biochemical outcomes from ARTO trial (NCT03449719) a phase II randomized trial testing association between abiraterone acetate and stereotactic body radiation therapy in castrate-resistant prostate cancer patients
- Author
-
Francolini, G., Detti, B., Di Cataldo, V., Caini, S., Alitto, A.R., S. Parisi, Demofonti, C., Bruni, A., Ingrosso, G., Timon, G., Allegra, A.G., Burchini, L., Salvestrini, V., Frosini, G., Cerbai, C., Visani, L., Becherini, C., Desideri, I., Meattini, I., and Livi, L.
- Published
- 2022
- Full Text
- View/download PDF
37. Epidemiology of Asthma in Adults of a community hospital. A cross-section study
- Author
-
María Laura Orazi, Claudio A S Parisi, Lucrecia Bustamante, Carolina Antonietti, Marcos Las Heras, Estefania Juszkiewicz Franze, Graciela Svetliza, Sergio Zunino, and Carla Ritchie
- Subjects
medicine.medical_specialty ,business.industry ,Cross-sectional study ,Family medicine ,Immunology ,Epidemiology ,Immunology and Allergy ,Medicine ,business ,medicine.disease ,Community hospital ,Asthma - Published
- 2020
38. Direct Medical Costs of Chronic Urticaria in a Private Health Organization of Buenos Aires, Argentina
- Author
-
Claudio A S Parisi, Christian Morelo Torres, Carla Ritchie, and Natalia Petriz
- Subjects
Adult ,medicine.medical_specialty ,Pediatrics ,Adolescent ,Urticaria ,Economics, Econometrics and Finance (miscellaneous) ,Argentina ,Disease ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Indirect costs ,0302 clinical medicine ,Health care ,Humans ,Medicine ,Medical prescription ,Child ,Pharmacology, Toxicology and Pharmaceutics (miscellaneous) ,Chronic urticaria ,Retrospective Studies ,Estimation ,business.industry ,Health Policy ,Health Care Costs ,Confidence interval ,030228 respiratory system ,Child, Preschool ,Chronic Disease ,Emergency medicine ,Allergists ,business - Abstract
Background Scarce studies address the issue of resource consumption and direct health care costs of patients diagnosed with adult-onset chronic urticaria (CU). Objectives To estimate medical resource consumption and direct health care costs of affected patients in a private health maintenance organization in Buenos Aires, Argentina. Methods Patients diagnosed with adult-onset CU ( International Classification of Diseases, Ninth Revision, Clinical Modification code 708.1, 708.8, or 708.9) and who were members of the Italian Hospital Medical Care Program were included in the study. All data on hospitalizations, drug prescription, outpatient episodes, consultations, and investigations/tests in the 12 months before inclusion in the study were considered for the estimation of medical resource consumption and direct health care costs. Third-quarter 2014 costs were obtained from the Italian Hospital Medical Care Program and converted into US dollars (using the November 2014 exchange rate). Results A total of 232 patients were included in the study. The mean age at diagnosis was 54.2 ± 20.0 years, and the mean disease duration was 5.4 ± 2.6 years (range, 2–22 years). Of the total number of patients, 75% had allergists as their usual source of care, 23% had dermatologists, 18% had internists, and 3% had rheumatologists. Only 7.8% of the patients had an emergency room admission to manage CU symptoms. To manage the disease, 57.8% of patients used antihistamines and 11.6% used oral corticosteroids. The most relevant source of cost was the medical treatment received, followed by physician visits. The average yearly direct cost per patient was US $1015 ± $752 (95% confidence interval 803–2003). Conclusions This is the first Argentine study that evaluated the costs of CU considering the direct medical costs of the disease. The study provides information on resource utilization and the disease-related economic burden, which is valuable to better understand CU in the local setting. Future research that takes into consideration the direct and indirect costs of the disease will expand knowledge and improve management of the disease.
- Published
- 2016
39. Chronic urticaria in a health maintenance organization of Buenos Aires, Argentina - new data that increase global knowledge of this disease
- Author
-
Natalia Petriz, Carla Ritchie, Claudio A S Parisi, Ana Giménez-Arnau, and Christian Morelo Torres
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Adolescent ,Urticaria ,Population ,Argentina ,Prevalence ,Urticaria -- Buenos Aires (Argentina) ,Disease ,Dermatology ,Chronic disease ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Age Distribution ,0302 clinical medicine ,Epidemiology ,medicine ,Humans ,Angioedema ,Child ,education ,Retrospective Studies ,Investigation ,education.field_of_study ,business.industry ,Medical record ,Health Maintenance Organizations ,Retrospective cohort study ,General Medicine ,Middle Aged ,030228 respiratory system ,El Niño ,RL1-803 ,Female ,medicine.symptom ,business - Abstract
Background: In spite of the frequency of chronic urticaria, there are no epidemiological studies on its prevalence in Argentina. Objective: The objective of this study was to define the prevalence and epidemiological characteristics of chronic urticaria patients in Buenos Aires. Methods: The population studied were the members of the Italian Hospital Medical Care Program, a prepaid health maintenance organization located in the urban areas around the Autonomous City of Buenos Aires, Argentina. All patients with diagnosis of chronic urticaria members of the Italian Hospital Medical Care Program, and with at least 12 months of follow up were included in the study. All medical records obtained between January 1st, 2012 and December 31, 2014 were analyzed. The prevalence ratio for chronic urticaria per 100,000 population with 95% CI for December 31, 2014 was calculated. The prevalence rate for the entire population and then discriminated for adults and pediatric patients (less than 18 years old at diagnosis) was assessed. Results: 158,926 members were analyzed. A total of 463 cases of chronic urticaria were identified on prevalence date (68 in pediatrics, 395 in adults), yielding a crude point prevalence ratio of 0.29% (CI 95% 0.26-0.31%). The observed prevalence of chronic urticaria in the adult population was 0.34 % (95% CI 0.31-0.38%), while in pediatrics it was 0.15 % (95% CI 0.11-0.20%). Study limitations: the main weakness is that the results were obtained from an HMO and therefore the possibility of selection bias. Conclusions: chronic urticaria is a global condition. Its prevalence in Buenos Aires is comparable with other countries.
- Published
- 2018
40. Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017
- Author
-
James, S.L. Abate, D. Abate, K.H. Abay, S.M. Abbafati, C. Abbasi, N. Abbastabar, H. Abd-Allah, F. Abdela, J. Abdelalim, A. Abdollahpour, I. Abdulkader, R.S. Abebe, Z. Abera, S.F. Abil, O.Z. Abraha, H.N. Abu-Raddad, L.J. Abu-Rmeileh, N.M.E. Accrombessi, M.M.K. Acharya, D. Acharya, P. Ackerman, I.N. Adamu, A.A. Adebayo, O.M. Adekanmbi, V. Adetokunboh, O.O. Adib, M.G. Adsuar, J.C. Afanvi, K.A. Afarideh, M. Afshin, A. Agarwal, G. Agesa, K.M. Aggarwal, R. Aghayan, S.A. Agrawal, S. Ahmadi, A. Ahmadi, M. Ahmadieh, H. Ahmed, M.B. Aichour, A.N. Aichour, I. Aichour, M.T.E. Akinyemiju, T. Akseer, N. Al-Aly, Z. Al-Eyadhy, A. Al-Mekhlafi, H.M. Al-Raddadi, R.M. Alahdab, F. Alam, K. Alam, T. Alashi, A. Alavian, S.M. Alene, K.A. Alijanzadeh, M. Alizadeh-Navaei, R. Aljunid, S.M. Alkerwi, A. Alla, F. Allebeck, P. Alouani, M.M.L. Altirkawi, K. Alvis-Guzman, N. Amare, A.T. Aminde, L.N. Ammar, W. Amoako, Y.A. Anber, N.H. Andrei, C.L. Androudi, S. Animut, M.D. Anjomshoa, M. Ansha, M.G. Antonio, C.A.T. Anwari, P. Arabloo, J. Arauz, A. Aremu, O. Ariani, F. Armoon, B. Ärnlöv, J. Arora, A. Artaman, A. Aryal, K.K. Asayesh, H. Asghar, R.J. Ataro, Z. Atre, S.R. Ausloos, M. Avila-Burgos, L. Avokpaho, E.F.G.A. Awasthi, A. Ayala Quintanilla, B.P. Ayer, R. Azzopardi, P.S. Babazadeh, A. Badali, H. Badawi, A. Bali, A.G. Ballesteros, K.E. Ballew, S.H. Banach, M. Banoub, J.A.M. Banstola, A. Barac, A. Barboza, M.A. Barker-Collo, S.L. Bärnighausen, T.W. Barrero, L.H. Baune, B.T. Bazargan-Hejazi, S. Bedi, N. Beghi, E. Behzadifar, M. Behzadifar, M. Béjot, Y. Belachew, A.B. Belay, Y.A. Bell, M.L. Bello, A.K. Bensenor, I.M. Bernabe, E. Bernstein, R.S. Beuran, M. Beyranvand, T. Bhala, N. Bhattarai, S. Bhaumik, S. Bhutta, Z.A. Biadgo, B. Bijani, A. Bikbov, B. Bilano, V. Bililign, N. Bin Sayeed, M.S. Bisanzio, D. Blacker, B.F. Blyth, F.M. Bou-Orm, I.R. Boufous, S. Bourne, R. Brady, O.J. Brainin, M. Brant, L.C. Brazinova, A. Breitborde, N.J.K. Brenner, H. Briant, P.S. Briggs, A.M. Briko, A.N. Britton, G. Brugha, T. Buchbinder, R. Busse, R. Butt, Z.A. Cahuana-Hurtado, L. Cano, J. Cárdenas, R. Carrero, J.J. Carter, A. Carvalho, F. Castañeda-Orjuela, C.A. Castillo Rivas, J. Castro, F. Catalá-López, F. Cercy, K.M. Cerin, E. Chaiah, Y. Chang, A.R. Chang, H.-Y. Chang, J.-C. Charlson, F.J. Chattopadhyay, A. Chattu, V.K. Chaturvedi, P. Chiang, P.P.-C. Chin, K.L. Chitheer, A. Choi, J.-Y.J. Chowdhury, R. Christensen, H. Christopher, D.J. Cicuttini, F.M. Ciobanu, L.G. Cirillo, M. Claro, R.M. Collado-Mateo, D. Cooper, C. Coresh, J. Cortesi, P.A. Cortinovis, M. Costa, M. Cousin, E. Criqui, M.H. Cromwell, E.A. Cross, M. Crump, J.A. Dadi, A.F. Dandona, L. Dandona, R. Dargan, P.I. Daryani, A. Das Gupta, R. Das Neves, J. Dasa, T.T. Davey, G. Davis, A.C. Davitoiu, D.V. De Courten, B. De La Hoz, F.P. De Leo, D. De Neve, J.-W. Degefa, M.G. Degenhardt, L. Deiparine, S. Dellavalle, R.P. Demoz, G.T. Deribe, K. Dervenis, N. Des Jarlais, D.C. Dessie, G.A. Dey, S. Dharmaratne, S.D. Dinberu, M.T. Dirac, M.A. Djalalinia, S. Doan, L. Dokova, K. Doku, D.T. Dorsey, E.R. Doyle, K.E. Driscoll, T.R. Dubey, M. Dubljanin, E. Duken, E.E. Duncan, B.B. Duraes, A.R. Ebrahimi, H. Ebrahimpour, S. Echko, M.M. Edvardsson, D. Effiong, A. Ehrlich, J.R. El Bcheraoui, C. El Sayed Zaki, M. El-Khatib, Z. Elkout, H. Elyazar, I.R.F. Enayati, A. Endries, A.Y. Er, B. Erskine, H.E. Eshrati, B. Eskandarieh, S. Esteghamati, A. Esteghamati, S. Fakhim, H. Fallah Omrani, V. Faramarzi, M. Fareed, M. Farhadi, F. Farid, T.A. Farinha, C.S.E. Farioli, A. Faro, A. Farvid, M.S. Farzadfar, F. Feigin, V.L. Fentahun, N. Fereshtehnejad, S.-M. Fernandes, E. Fernandes, J.C. Ferrari, A.J. Feyissa, G.T. Filip, I. Fischer, F. Fitzmaurice, C. Foigt, N.A. Foreman, K.J. Fox, J. Frank, T.D. Fukumoto, T. Fullman, N. Fürst, T. Furtado, J.M. Futran, N.D. Gall, S. Ganji, M. Gankpe, F.G. Garcia-Basteiro, A.L. Gardner, W.M. Gebre, A.K. Gebremedhin, A.T. Gebremichael, T.G. Gelano, T.F. Geleijnse, J.M. Genova-Maleras, R. Geramo, Y.C.D. Gething, P.W. Gezae, K.E. Ghadiri, K. Ghasemi Falavarjani, K. Ghasemi-Kasman, M. Ghimire, M. Ghosh, R. Ghoshal, A.G. Giampaoli, S. Gill, P.S. Gill, T.K. Ginawi, I.A. Giussani, G. Gnedovskaya, E.V. Goldberg, E.M. Goli, S. Gómez-Dantés, H. Gona, P.N. Gopalani, S.V. Gorman, T.M. Goulart, A.C. Goulart, B.N.G. Grada, A. Grams, M.E. Grosso, G. Gugnani, H.C. Guo, Y. Gupta, P.C. Gupta, R. Gupta, R. Gupta, T. Gyawali, B. Haagsma, J.A. Hachinski, V. Hafezi-Nejad, N. Haghparast Bidgoli, H. Hagos, T.B. Hailu, G.B. Haj-Mirzaian, A. Haj-Mirzaian, A. Hamadeh, R.R. Hamidi, S. Handal, A.J. Hankey, G.J. Hao, Y. Harb, H.L. Harikrishnan, S. Haro, J.M. Hasan, M. Hassankhani, H. Hassen, H.Y. Havmoeller, R. Hawley, C.N. Hay, R.J. Hay, S.I. Hedayatizadeh-Omran, A. Heibati, B. Hendrie, D. Henok, A. Herteliu, C. Heydarpour, S. Hibstu, D.T. Hoang, H.T. Hoek, H.W. Hoffman, H.J. Hole, M.K. Homaie Rad, E. Hoogar, P. Hosgood, H.D. Hosseini, S.M. Hosseinzadeh, M. Hostiuc, M. Hostiuc, S. Hotez, P.J. Hoy, D.G. Hsairi, M. Htet, A.S. Hu, G. Huang, J.J. Huynh, C.K. Iburg, K.M. Ikeda, C.T. Ileanu, B. Ilesanmi, O.S. Iqbal, U. Irvani, S.S.N. Irvine, C.M.S. Mohammed, S. Islam, S. Islami, F. Jacobsen, K.H. Jahangiry, L. Jahanmehr, N. Jain, S.K. Jakovljevic, M. Javanbakht, M. Jayatilleke, A.U. Jeemon, P. Jha, R.P. Jha, V. Ji, J.S. Johnson, C.O. Jonas, J.B. Jozwiak, J.J. Jungari, S.B. Jürisson, M. Kabir, Z. Kadel, R. Kahsay, A. Kalani, R. Kanchan, T. Karami, M. Karami Matin, B. Karch, A. Karema, C. Karimi, N. Karimi, S.M. Kasaeian, A. Kassa, D.H. Kassa, G.M. Kassa, T.D. Kassebaum, N.J. Katikireddi, S.V. Kawakami, N. Kazemi Karyani, A. Keighobadi, M.M. Keiyoro, P.N. Kemmer, L. Kemp, G.R. Kengne, A.P. Keren, A. Khader, Y.S. Khafaei, B. Khafaie, M.A. Khajavi, A. Khalil, I.A. Khan, E.A. Khan, M.S. Khan, M.A. Khang, Y.-H. Khazaei, M. Khoja, A.T. Khosravi, A. Khosravi, M.H. Kiadaliri, A.A. Kiirithio, D.N. Kim, C.-I. Kim, D. Kim, P. Kim, Y.-E. Kim, Y.J. Kimokoti, R.W. Kinfu, Y. Kisa, A. Kissimova-Skarbek, K. Kivimäki, M. Knudsen, A.K.S. Kocarnik, J.M. Kochhar, S. Kokubo, Y. Kolola, T. Kopec, J.A. Kosen, S. Kotsakis, G.A. Koul, P.A. Koyanagi, A. Kravchenko, M.A. Krishan, K. Krohn, K.J. Kuate Defo, B. Kucuk Bicer, B. Kumar, G.A. Kumar, M. Kyu, H.H. Lad, D.P. Lad, S.D. Lafranconi, A. Lalloo, R. Lallukka, T. Lami, F.H. Lansingh, V.C. Latifi, A. Lau, K.M.-M. Lazarus, J.V. Leasher, J.L. Ledesma, J.R. Lee, P.H. Leigh, J. Leung, J. Levi, M. Lewycka, S. Li, S. Li, Y. Liao, Y. Liben, M.L. Lim, L.-L. Lim, S.S. Liu, S. Lodha, R. Looker, K.J. Lopez, A.D. Lorkowski, S. Lotufo, P.A. Low, N. Lozano, R. Lucas, T.C.D. Lucchesi, L.R. Lunevicius, R. Lyons, R.A. Ma, S. Macarayan, E.R.K. Mackay, M.T. Madotto, F. Magdy Abd El Razek, H. Magdy Abd El Razek, M. Maghavani, D.P. Mahotra, N.B. Mai, H.T. Majdan, M. Majdzadeh, R. Majeed, A. Malekzadeh, R. Malta, D.C. Mamun, A.A. Manda, A.-L. Manguerra, H. Manhertz, T. Mansournia, M.A. Mantovani, L.G. Mapoma, C.C. Maravilla, J.C. Marcenes, W. Marks, A. Martins-Melo, F.R. Martopullo, I. März, W. Marzan, M.B. Mashamba-Thompson, T.P. Massenburg, B.B. Mathur, M.R. Matsushita, K. Maulik, P.K. Mazidi, M. McAlinden, C. McGrath, J.J. McKee, M. Mehndiratta, M.M. Mehrotra, R. Mehta, K.M. Mehta, V. Mejia-Rodriguez, F. Mekonen, T. Melese, A. Melku, M. Meltzer, M. Memiah, P.T.N. Memish, Z.A. Mendoza, W. Mengistu, D.T. Mengistu, G. Mensah, G.A. Mereta, S.T. Meretoja, A. Meretoja, T.J. Mestrovic, T. Mezerji, N.M.G. Miazgowski, B. Miazgowski, T. Millear, A.I. Miller, T.R. Miltz, B. Mini, G.K. Mirarefin, M. Mirrakhimov, E.M. Misganaw, A.T. Mitchell, P.B. Mitiku, H. Moazen, B. Mohajer, B. Mohammad, K.A. Mohammadifard, N. Mohammadnia-Afrouzi, M. Mohammed, M.A. Mohammed, S. Mohebi, F. Moitra, M. Mokdad, A.H. Molokhia, M. Monasta, L. Moodley, Y. Moosazadeh, M. Moradi, G. Moradi-Lakeh, M. Moradinazar, M. Moraga, P. Morawska, L. Moreno Velásquez, I. Morgado-Da-Costa, J. Morrison, S.D. Moschos, M.M. Mousavi, S.M. Mruts, K.B. Muche, A.A. Muchie, K.F. Mueller, U.O. Muhammed, O.S. Mukhopadhyay, S. Muller, K. Mumford, J.E. Murhekar, M. Musa, J. Musa, K.I. Mustafa, G. Nabhan, A.F. Nagata, C. Naghavi, M. Naheed, A. Nahvijou, A. Naik, G. Naik, N. Najafi, F. Naldi, L. Nam, H.S. Nangia, V. Nansseu, J.R. Nascimento, B.R. Natarajan, G. Neamati, N. Negoi, I. Negoi, R.I. Neupane, S. Newton, C.R.J. Ngunjiri, J.W. Nguyen, A.Q. Nguyen, H.T. Nguyen, H.L.T. Nguyen, H.T. Nguyen, L.H. Nguyen, M. Nguyen, N.B. Nguyen, S.H. Nichols, E. Ningrum, D.N.A. Nixon, M.R. Nolutshungu, N. Nomura, S. Norheim, O.F. Noroozi, M. Norrving, B. Noubiap, J.J. Nouri, H.R. Nourollahpour Shiadeh, M. Nowroozi, M.R. Nsoesie, E.O. Nyasulu, P.S. Odell, C.M. Ofori-Asenso, R. Ogbo, F.A. Oh, I.-H. Oladimeji, O. Olagunju, A.T. Olagunju, T.O. Olivares, P.R. Olsen, H.E. Olusanya, B.O. Ong, K.L. Ong, S.K. Oren, E. Ortiz, A. Ota, E. Otstavnov, S.S. øverland, S. Owolabi, M.O. Mahesh, P.A. Pacella, R. Pakpour, A.H. Pana, A. Panda-Jonas, S. Parisi, A. Park, E.-K. Parry, C.D.H. Patel, S. Pati, S. Patil, S.T. Patle, A. Patton, G.C. Paturi, V.R. Paulson, K.R. Pearce, N. Pereira, D.M. Perico, N. Pesudovs, K. Pham, H.Q. Phillips, M.R. Pigott, D.M. Pillay, J.D. Piradov, M.A. Pirsaheb, M. Pishgar, F. Plana-Ripoll, O. Plass, D. Polinder, S. Popova, S. Postma, M.J. Pourshams, A. Poustchi, H. Prabhakaran, D. Prakash, S. Prakash, V. Purcell, C.A. Purwar, M.B. Qorbani, M. Quistberg, D.A. Radfar, A. Rafay, A. Rafiei, A. Rahim, F. Rahimi, K. Rahimi-Movaghar, A. Rahimi-Movaghar, V. Rahman, M. Ur Rahman, M.H. Rahman, M.A. Rahman, S.U. Rai, R.K. Rajati, F. Ram, U. Ranjan, P. Ranta, A. Rao, P.C. Rawaf, D.L. Rawaf, S. Reddy, K.S. Reiner, R.C. Reinig, N. Reitsma, M.B. Remuzzi, G. Renzaho, A.M.N. Resnikoff, S. Rezaei, S. Rezai, M.S. Ribeiro, A.L.P. Robinson, S.R. Roever, L. Ronfani, L. Roshandel, G. Rostami, A. Roth, G.A. Roy, A. Rubagotti, E. Sachdev, P.S. Sadat, N. Saddik, B. Sadeghi, E. Saeedi Moghaddam, S. Safari, H. Safari, Y. Safari-Faramani, R. Safdarian, M. Safi, S. Safiri, S. Sagar, R. Sahebkar, A. Sahraian, M.A. Sajadi, H.S. Salam, N. Salama, J.S. Salamati, P. Saleem, K. Saleem, Z. Salimi, Y. Salomon, J.A. Salvi, S.S. Salz, I. Samy, A.M. Sanabria, J. Sang, Y. Santomauro, D.F. Santos, I.S. Santos, J.V. Santric Milicevic, M.M. Sao Jose, B.P. Sardana, M. Sarker, A.R. Sarrafzadegan, N. Sartorius, B. Sarvi, S. Sathian, B. Satpathy, M. Sawant, A.R. Sawhney, M. Saxena, S. Saylan, M. Schaeffner, E. Schmidt, M.I. Schneider, I.J.C. Schöttker, B. Schwebel, D.C. Schwendicke, F. Scott, J.G. Sekerija, M. Sepanlou, S.G. Serván-Mori, E. Seyedmousavi, S. Shabaninejad, H. Shafieesabet, A. Shahbazi, M. Shaheen, A.A. Shaikh, M.A. Shams-Beyranvand, M. Shamsi, M. Shamsizadeh, M. Sharafi, H. Sharafi, K. Sharif, M. Sharif-Alhoseini, M. Sharma, M. Sharma, R. She, J. Sheikh, A. Shi, P. Shibuya, K. Shigematsu, M. Shiri, R. Shirkoohi, R. Shishani, K. Shiue, I. Shokraneh, F. Shoman, H. Shrime, M.G. Si, S. Siabani, S. Siddiqi, T.J. Sigfusdottir, I.D. Sigurvinsdottir, R. Silva, J.P. Silveira, D.G.A. Singam, N.S.V. Singh, J.A. Singh, N.P. Singh, V. Sinha, D.N. Skiadaresi, E. Slepak, E.L.N. Sliwa, K. Smith, D.L. Smith, M. Soares Filho, A.M. Sobaih, B.H. Sobhani, S. Sobngwi, E. Soneji, S.S. Soofi, M. Soosaraei, M. Sorensen, R.J.D. Soriano, J.B. Soyiri, I.N. Sposato, L.A. Sreeramareddy, C.T. Srinivasan, V. Stanaway, J.D. Stein, D.J. Steiner, C. Steiner, T.J. Stokes, M.A. Stovner, L.J. Subart, M.L. Sudaryanto, A. Sufiyan, M.B. Sunguya, B.F. Sur, P.J. Sutradhar, I. Sykes, B.L. Sylte, D.O. Tabarés-Seisdedos, R. Tadakamadla, S.K. Tadesse, B.T. Tandon, N. Tassew, S.G. Tavakkoli, M. Taveira, N. Taylor, H.R. Tehrani-Banihashemi, A. Tekalign, T.G. Tekelemedhin, S.W. Tekle, M.G. Temesgen, H. Temsah, M.-H. Temsah, O. Terkawi, A.S. Teweldemedhin, M. Thankappan, K.R. Thomas, N. Tilahun, B. To, Q.G. Tonelli, M. Topor-Madry, R. Topouzis, F. Torre, A.E. Tortajada-Girbés, M. Touvier, M. Tovani-Palone, M.R. Towbin, J.A. Tran, B.X. Tran, K.B. Troeger, C.E. Truelsen, T.C. Tsilimbaris, M.K. Tsoi, D. Tudor Car, L. Tuzcu, E.M. Ukwaja, K.N. Ullah, I. Undurraga, E.A. Unutzer, J. Updike, R.L. Usman, M.S. Uthman, O.A. Vaduganathan, M. Vaezi, A. Valdez, P.R. Varughese, S. Vasankari, T.J. Venketasubramanian, N. Villafaina, S. Violante, F.S. Vladimirov, S.K. Vlassov, V. Vollset, S.E. Vosoughi, K. Vujcic, I.S. Wagnew, F.S. Waheed, Y. Waller, S.G. Wang, Y. Wang, Y.-P. Weiderpass, E. Weintraub, R.G. Weiss, D.J. Weldegebreal, F. Weldegwergs, K.G. Werdecker, A. West, T.E. Whiteford, H.A. Widecka, J. Wijeratne, T. Wilner, L.B. Wilson, S. Winkler, A.S. Wiyeh, A.B. Wiysonge, C.S. Wolfe, C.D.A. Woolf, A.D. Wu, S. Wu, Y.-C. Wyper, G.M.A. Xavier, D. Xu, G. Yadgir, S. Yadollahpour, A. Yahyazadeh Jabbari, S.H. Yamada, T. Yan, L.L. Yano, Y. Yaseri, M. Yasin, Y.J. Yeshaneh, A. Yimer, E.M. Yip, P. Yisma, E. Yonemoto, N. Yoon, S.-J. Yotebieng, M. Younis, M.Z. Yousefifard, M. Yu, C. Zadnik, V. Zaidi, Z. Zaman, S.B. Zamani, M. Zare, Z. Zeleke, A.J. Zenebe, Z.M. Zhang, K. Zhao, Z. Zhou, M. Zodpey, S. Zucker, I. Vos, T. Murray, C.J.L. GBD 2017 Disease Injury Incidence Prevalence Collaborators
- Abstract
Background: The Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017) includes a comprehensive assessment of incidence, prevalence, and years lived with disability (YLDs) for 354 causes in 195 countries and territories from 1990 to 2017. Previous GBD studies have shown how the decline of mortality rates from 1990 to 2016 has led to an increase in life expectancy, an ageing global population, and an expansion of the non-fatal burden of disease and injury. These studies have also shown how a substantial portion of the world's population experiences non-fatal health loss with considerable heterogeneity among different causes, locations, ages, and sexes. Ongoing objectives of the GBD study include increasing the level of estimation detail, improving analytical strategies, and increasing the amount of high-quality data. Methods: We estimated incidence and prevalence for 354 diseases and injuries and 3484 sequelae. We used an updated and extensive body of literature studies, survey data, surveillance data, inpatient admission records, outpatient visit records, and health insurance claims, and additionally used results from cause of death models to inform estimates using a total of 68 781 data sources. Newly available clinical data from India, Iran, Japan, Jordan, Nepal, China, Brazil, Norway, and Italy were incorporated, as well as updated claims data from the USA and new claims data from Taiwan (province of China) and Singapore. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between rates of incidence, prevalence, remission, and cause of death for each condition. YLDs were estimated as the product of a prevalence estimate and a disability weight for health states of each mutually exclusive sequela, adjusted for comorbidity. We updated the Socio-demographic Index (SDI), a summary development indicator of income per capita, years of schooling, and total fertility rate. Additionally, we calculated differences between male and female YLDs to identify divergent trends across sexes. GBD 2017 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting. Findings: Globally, for females, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and haemoglobinopathies and haemolytic anaemias in both 1990 and 2017. For males, the causes with the greatest age-standardised prevalence were oral disorders, headache disorders, and tuberculosis including latent tuberculosis infection in both 1990 and 2017. In terms of YLDs, low back pain, headache disorders, and dietary iron deficiency were the leading Level 3 causes of YLD counts in 1990, whereas low back pain, headache disorders, and depressive disorders were the leading causes in 2017 for both sexes combined. All-cause age-standardised YLD rates decreased by 3·9% (95% uncertainty interval [UI] 3·1-4·6) from 1990 to 2017; however, the all-age YLD rate increased by 7·2% (6·0-8·4) while the total sum of global YLDs increased from 562 million (421-723) to 853 million (642-1100). The increases for males and females were similar, with increases in all-age YLD rates of 7·9% (6·6-9·2) for males and 6·5% (5·4-7·7) for females. We found significant differences between males and females in terms of age-standardised prevalence estimates for multiple causes. The causes with the greatest relative differences between sexes in 2017 included substance use disorders (3018 cases [95% UI 2782-3252] per 100 000 in males vs 1400 [1279-1524] per 100 000 in females), transport injuries (3322 [3082-3583] vs 2336 [2154-2535]), and self-harm and interpersonal violence (3265 [2943-3630] vs 5643 [5057-6302]). Interpretation: Global all-cause age-standardised YLD rates have improved only slightly over a period spanning nearly three decades. However, the magnitude of the non-fatal disease burden has expanded globally, with increasing numbers of people who have a wide spectrum of conditions. A subset of conditions has remained globally pervasive since 1990, whereas other conditions have displayed more dynamic trends, with different ages, sexes, and geographies across the globe experiencing varying burdens and trends of health loss. This study emphasises how global improvements in premature mortality for select conditions have led to older populations with complex and potentially expensive diseases, yet also highlights global achievements in certain domains of disease and injury. Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
- Published
- 2018
41. Neuromuscular taping enhances hand function in patients with systemic sclerosis: a pilot study
- Author
-
S, Parisi, C, Celletti, M, Scarati, M, Priora, A, Laganà, C L, Peroni, F, Camerota, G, La Torre, D, Blow, and E, Fusaro
- Subjects
Scleroderma, Systemic ,Physical Stimulation ,Humans ,Pain ,Female ,Pilot Projects ,Middle Aged ,Hand - Abstract
Hand functioning is often impaired in patients with Systemic sclerosis. Neuromuscular Taping is a novel application of tape able to improve functioning. The aim of this study was to evaluate the possible role of this application in the hand functionality of patients with Systemic sclerosis. Women with a diagnosis of SSc has been recruited and evaluated using different scales before and immediately after NMT application and after one, three and six months. Fifty-three women has been evaluated and Cochin Hand Functional Disability scale, Hand Mobility in Sclerodermia, Modified Rodnan Skin Score and Dreiser Algo - Functional Index scores showed statistical significant differences during all the period; moreover a reduction of pain and Raynaud Phenomenon's and an improvement of finger flexion has been observed. Application of NMT in patients with Systemic sclerosis have showed beneficial effect and future studies are needed to confirm these results.
- Published
- 2017
42. Strategies for compliance with the internship program among three pediatric interns with latex allergy
- Author
-
Alfredo Eymann, Stefanía Barbariol, Claudio A S Parisi, and Julián Llera
- Subjects
Adult ,030213 general clinical medicine ,medicine.medical_specialty ,Hospital setting ,education ,Hand Dermatoses ,030204 cardiovascular system & hematology ,Pediatrics ,Compliance (psychology) ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Latex Hypersensitivity ,Internship ,Intensive care ,Humans ,Medicine ,health care economics and organizations ,business.industry ,Internship and Residency ,medicine.disease ,Latex allergy ,Family medicine ,Pediatrics, Perinatology and Child Health ,business ,Symptom exacerbation - Abstract
Latex allergy is common in the hospital setting.To describe the clinical situation of three pediatric interns with latex allergy and the prevention strategies implemented during clinical clerkships in pediatric and neonatal intensive care units.The three interns referred symptom exacerbation during their internship program. Diagnosis was confirmed based on a compatible history and positive specific immunoglobulin E. A semi-structured interview was done to describe perceptions about prevention strategies, the personnel were trained, and nitrile gloves were provided for carrying out procedures. Interns completed their clinical clerkships without having allergic reactions. Positive aspects referred by interns were that they felt cared for and experienced an improved quality of life; negative aspects were a bad predisposition and resistance against change among some other interns. Strategies designed to this end permitted interns to continue their internship program.La alergia al látex es frecuente en ámbitos hospitalarios.Describir la situación clínica de tres residentes de Pediatría con alergia al látex y las estrategias de prevención en las rotaciones de Terapia Intensiva Pediátrica y Neonatal.Las tres profesionales manifestaron exacerbación de síntomas durante la residencia. Se confirmó el diagnóstico con historia compatible e inmunoglobulina E específica positiva. Se realizó una entrevista semiestructurada para describir sus percepciones en relación con las estrategias de prevención, se capacitó al personal y se incorporaron guantes de nitrilo para los procedimientos. Las residentes realizaron las rotaciones sin presentar manifestaciones alérgicas. Refirieron como aspectos positivos sentirse cuidadas y mejor calidad de vida; como aspectos negativos, mala predisposición y resistencia al cambio en algunos compañeros. Las estrategias diseñadas permitieron que las residentes pudieran continuar su programa de formación.
- Published
- 2017
43. Prevalence of cow's milk protein allergy among children in a university community hospital
- Author
-
Romina Mehaudy, Claudio A S Parisi, Marina Orsi, María B Jauregui, Natalia Petriz, and Alfredo Eymann
- Subjects
0301 basic medicine ,Male ,Pediatrics ,medicine.medical_specialty ,Allergy ,Population ,Argentina ,Hospitals, Community ,Disease ,Cohort Studies ,Hospitals, University ,03 medical and health sciences ,0302 clinical medicine ,Food allergy ,Health care ,Prevalence ,Medicine ,Humans ,education ,Retrospective Studies ,education.field_of_study ,University community ,business.industry ,Infant ,Retrospective cohort study ,medicine.disease ,Milk Proteins ,Confidence interval ,030104 developmental biology ,Pediatrics, Perinatology and Child Health ,030211 gastroenterology & hepatology ,Female ,Milk Hypersensitivity ,business - Abstract
Cow's milk protein allergy (CMPA) is the most common food allergy in pediatrics. In Argentina, the prevalence of this disease has been evaluated in a few trials.To estimate the prevalence of CMPA and describe its variation throughout a period of 11 years.A retrospective cohort study was carried out in live newborn infants enrolled in a health care program of a university community hospital.One hundred and sixteen cases of children with CMPA were identified. Cumulative prevalence was 0.8% (95% confidence interval [CI]: 0.65-0.95). A percent increase of 0.4% in 2004 to 1.2% in 2014 was observed in the number of cases per year.In 2014, CMPA prevalence was 1.2%, i.e. three times that of 2004.La alergia a la proteína de la leche de vaca (APLV) es la alergia alimentaria más frecuente en pediatría. Existen pocos estudios que han evaluado la prevalencia de esta enfermedad en Argentina. Objetivos. Estimar la prevalencia de la APLV y describir su variación durante un período de 11 años. Pacientes y métodos. Se realizó un estudio de cohorte retrospectivo en recién nacidos vivos pertenecientes al programa de atención médica de un hospital universitario de comunidad. Resultados. Se identificaron 116 casos de niños con APLV. La prevalencia acumulada fue de 0,8% (intervalo de confianza –IC– 95%: 0,65-0,95). Se observó un incremento porcentual de casos por año, de 0,4% en 2004 a 1,2% en 2014. Conclusión. La prevalencia de APLV fue del 1,2% en 2014, tres veces superior a la prevalencia en 2004.
- Published
- 2017
44. El constitucionalismo social en la Constitución mexicana y su vasta influencia en el derecho argentino
- Author
-
Patricio Alejandro Maraniello and Néstor S. Parisi
- Subjects
General Medicine - Abstract
Existe la idea de que la entera organización del Estado, a través de sus distintos órganos, debe estar inspirada en fundamentos de políticas sociales, comenzando por el reconocimiento explícito de los derechos sociales y su consecuente acompañamiento de herramientas. Un elemento clave del Estado constitucional y democrático de derecho es la justicia constitucional. Esta intenta concretar los límites del poder estatal en expansión. El modelo constitucional del estado social y democrático de derecho es el resultado de un proceso evolutivo y de transformación del Estado liberal clásico. El Estado social de derecho acoge los valores jurídico-políticos clásicos. El constitucionalismo social mexicano, mediante su Carta Magna y su directa influencia con la Constitución de la Nación Argentina, dan cuenta de ello.
- Published
- 2017
45. Economic evaluation of Peek (Portable Eye Examination Kit) for diabetic retinopathy screening
- Author
-
S Parisi, H Philippin, Matthew J. Burton, N Sawers, M Gomes, and A Bastawrous
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,Eye examination ,business.industry ,Ophthalmology ,Economic evaluation ,Public Health, Environmental and Occupational Health ,medicine ,Peek ,Diabetic retinopathy ,medicine.disease ,business - Published
- 2016
46. Prevalencia de alergia al látex en una población de pacientes con diagnóstico de mielomeningocele
- Author
-
Natalia Petriz, Claudio A S Parisi, María C Cortines, Francisco de Badiola, Julio Busaniche, Santiago A Portillo, and Fernando A Frangi
- Subjects
Pediatrics, Perinatology and Child Health - Published
- 2016
47. Th-17 cytokines and interstitial lung involvement in systemic sclerosis
- Author
-
Giovanni Rolla, Enrico Fusaro, S Parisi, Maria Carla Cassinis, Enrico Heffler, Caterina Bucca, Francesca Angelino, Stefania Nicola, Clara Lisa Peroni, Monica Boita, Andrea Ferraris, and Luisa Brussino
- Subjects
Adult ,Male ,0301 basic medicine ,Pulmonary and Respiratory Medicine ,medicine.medical_treatment ,Scleroderma ,Carbon monoxide diffusing capacity ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,In patient ,Exhaled breath condensate ,Aged ,Aged, 80 and over ,030203 arthritis & rheumatology ,Scleroderma, Systemic ,Lung ,business.industry ,Interleukin-17 ,Interstitial lung disease ,Middle Aged ,medicine.disease ,Lung involvement ,respiratory tract diseases ,030104 developmental biology ,medicine.anatomical_structure ,Cytokine ,Breath Tests ,Immunology ,Cytokines ,Female ,Lung Diseases, Interstitial ,business - Abstract
The two phenotypes of both limited and diffuse systemic sclerosis (SSc) have different forms of pulmonary involvement: pulmonary arterial hypertension (limited phenotype) or interstitial lung disease (ILD) (diffuse phenotype). We aimed to investigate whether Th17-related cytokines, as measured in exhaled breath condensate (EBC) and in serum were connected to ILD in diffuse SSc patients. We found that for both limited and diffuse SSc, the EBC levels of all cytokines and most of the cytokine serum levels were significantly higher in patients than in controls, while, the EBC levels of Th-17 cytokines and the serum levels of IL-10 and TNF-α were significantly higher in diffuse than in limited SSc. Moreover, the thoracic CT-scan score of ILD was significantly associated with the EBC levels of IL-1 beta and with the serum IL-23, TNF-α and IL-10 levels, whereas lung carbon monoxide diffusing capacity was negatively related to the EBC levels of IL-1 beta, IL-17 and serum IL-10. Serum IL-23 was also inversely correlated with vital capacity. In conclusion, in diffuse SSc patients our results show a clear link between Th-17 cytokines measured both in EBC and in serum with interstitial lung involvement. This highlights how important it is to target Th-17 cytokines when developing new treatments for lung fibrosis.
- Published
- 2016
48. Clinical Nephrology - Epidemiology II
- Author
-
H. Agnes, P. Kalman, A. Jozsef, B. Henrik, I. Mucsi, K. Kamata, T. Sano, S. Naito, T. Okamoto, C. Okina, M. Kamata, J. Murano, K. Kobayashi, M. Uchida, T. Aoyama, Y. Takeuchi, Y. Nagaba, H. Sakamoto, C. Torino, V. Panuccio, A. Clementi, M. Garozzo, G. Bonanno, R. Boito, G. Natale, T. Cicchetti, A. Chippari, D. Logozzo, G. Alati, S. Cassani, A. Sellaro, G. D'arrigo, G. Tripepi, A. Roberta, M. Postorino, F. Mallamaci, C. Zoccali, E. Buonanno, S. Brancaccio, V. Fimiani, P. Napolitano, R. Spadola, L. Morrone, B. DI Iorio, D. Russo, A. Betriu, M. Martinez-Alonso, T. Vidal, J. Valdivielso, E. Fernandez, F. Bernadette, B. Jean-Baptiste, L. Frimat, N. D. Madala, G. P. Thusi, N. Sibisi, B. G. Mazibuko, A. G. H. Assounga, N.-C. Tsai, H.-H. Wang, Y.-C. Chen, C.-C. Hung, S.-J. Hwang, H.-C. Chen, P. Branco, T. Adragao, R. Birne, A. R. Martins, R. Vizinho, A. Gaspar, M. J. Grilo, J. D. Barata, D. Bonhorst, P. Adragao, J. S. Kim, J. W. Yang, M. K. Kim, S. O. Choi, B. G. Han, N. Nathalie, E. Sunny, G. Glorieux, B. Daniela, B. Fellype, L. Sophie, L. Horst D, M. Ziad, V. Raymond, M. Yanai, K. Okada, K. Takeuchi, K. Nitta, S. Takahashi, M. Morena, I. Jaussent, A. Halkovich, A.-M. Dupuy, A.-S. Bargnoux, L. Chenine, H. Leray-Moragues, K. Klouche, H. Vernhet, B. Canaud, J.-P. Cristol, A. Shutov, V. Serov, J. Kuznetsova, M. Menzorov, D. Serova, L. Petrescu, A. Zugravu, C. Capusa, S. Stancu, S. Cinca, C. Anghel, D. Timofte, L. Medrihan, D. Ionescu, G. Mircescu, T.-W. Hsu, K.-L. Kuo, S.-C. Hung, D.-C. Tarng, S. Lee, I. Kim, D. Lee, H. Rhee, S. Song, E. Seong, I. Kwak, M. Holzmann, C. Gardell, A. Jeppsson, U. Sartipy, Y. Solak, M. I. Yilmaz, K. Caglar, M. Saglam, H. Yaman, A. Sonmez, H. U. Unal, M. Gok, A. Gaipov, M. Kayrak, T. Eyileten, S. Turk, A. Vural, L. DI Lullo, F. Floccari, R. Rivera, A. Granata, A. D'amelio, F. Logias, G. Otranto, M. Malaguti, A. Santoboni, F. Fiorini, T. Connor, D. Oygar, D. Nitsch, D. Gale, R. Steenkamp, G. H. Neild, P. Maxwell, I. Louise Hogsbro, B. Redal-Baigorri, B. Sautenet, J. M. Halimi, A. Caille, P. Goupille, B. Giraudeau, Y. Oguz, M. Yenicesu, H. Cetinkaya, Y. Ishimoto, T. Ohki, M. Sugahara, T. Kanemitsu, M. Kobayashi, L. Uchida, N. Kotera, S. Tanaka, T. Sugimoto, N. Mise, N. Miyazaki, J. Matsumoto, I. Murata, G. Yoshida, K. Morishita, H. Ushikoshi, K. Nishigaki, S. Ogura, S. Minatoguchi, R. Harvey, A. Ala, D. Banerjee, C. Farmer, J. Irving, H. Hobbs, T. Wheeler, B. Klebe, P. Stevens, G. Selim, O. Stojceva-Taneva, L. Tozija, N. Stojcev, S. Gelev, P. Dzekova-Vidimliski, S. Pavleska, A. Sikole, A. R. Qureshi, M. Evans, M. Stendahl, K. G. Prutz, C. G. Elinder, K. Tamagaki, H. Kado, M. Nakata, T. Kitani, N. Ota, R. Ishida, E. Matsuoka, Y. Shiotsu, M. Ishida, Y. Mori, M. Christelle, N. Rognant, D. Evelyne, F. Sophie, J. Laurent, L. Maurice, R. Silverwood, M. Pierce, D. Kuh, C. Savage, C. Ferro, D. G. Moniek, M. De Goeij, H. Nynke, O. Gurbey, R. Joris, D. Friedo, P. Clayton, B. Grace, A. Cass, S. Mcdonald, V. Lorenzo, M. Martin Conde, A. Dusso, J. M. Valdivielso, D. P. Roggeri, G. Cannella, M. Cozzolino, S. Mazzaferro, P. Messa, D. Brancaccio, R. De Souza Faria, N. Fernandes, J. Lovisi, M. Moura Marta, M. Reboredo, B. Do Vale Pinheiro, M. Bastos, F. Hundt, S. Pabst, C. Hammerstingl, T. Gerhardt, D. Skowasch, R. Woitas, A. A. Lopes, L. F. Silva, C. M. Matos, M. S. Martins, F. A. Silva, G. B. Lopes, F. Pizzarelli, P. Dattolo, S. Michelassi, C. Rossi, S. Bandinelli, M. Mieth, R. Mass, L. Ferrucci, S. Parisi, S. Arduino, R. Attini, F. Fassio, M. Biolcati, A. Pagano, C. Bossotti, M. Ferraresi, P. Gaglioti, T. Todros, G. B. Piccoli, T. M. Salgado, B. Arguello, S. I. Benrimoj, F. Fernandez-Llimos, P. Bailey, C. Tomson, Y. Ben-Shlomo, A. Santoro, P. Rucci, M. Mandreoli, F. Caruso, M. Corradini, M. Flachi, D. Gibertoni, A. Rigotti, G. Russo, M. Fantini, H. S. Mahapatra, S. Choudhury, G. Buxi, N. Sharma, Y. Gupta, V. Sekhar, N. Yanagisawa, M. Ando, A. Ajisawa, K. Tsuchiya, O. Janusz, M. Mikolaj, M. Jacek, R. Boleslaw, S. Prakash, R. Coffin, J. Schold, D. Einstadter, S. Stark, D. Rodgers, M. Howard, A. Sehgal, S. Palmer, A. Tong, B. Manns, J. Craig, M. Ruospo, L. Gargano, G. Strippoli, M. Vecchio, M. Petruzzi, M. De Benedictis, F. Pellegrini, Y. Ohno, E. Ishimura, T. Naganuma, K. Kondo, W. Fukushima, K. Mui, M. Inaba, Y. Hirota, X. Sun, S. Jiang, H. Gu, Y. Chen, C. XI, X. Qiao, X. Chen, E. Daher, G. S. Junior, C. N. Jacinto, R. S. Pimentel, G. B. R. Aguiar, C. B. Lima, R. C. Borges, L. P. C. Mota, J. V. L. Melo, S. A. Melo, V. T. Canamary, M. Alves, S. M. H. A. Araujo, Y. K. Huang, K. Rogacev, B. Cremers, A. Zawada, S. Seiler, N. Binder, P. Ege, G. Grosse-Dunker, I. Heisel, F. Hornof, J. Jeken, N. Rebling, C. Ulrich, B. Scheller, M. Bohm, D. Fliser, G. H. Heine, B. Robinson, M. Wang, B. Bieber, R. Fluck, P. G. Kerr, B. Wikstrom, M. Krishnan, A. Nissenson, R. L. Pisoni, S. Mykleset, T. B. Osthus, B. Waldum, I. Os, J. Buttigieg, A. Cassar, J. Farrugia Agius, M. Hara, M. Yamato, K. Yasuda, and K. Sasaki
- Subjects
Transplantation ,medicine.medical_specialty ,Acute coronary syndrome ,business.industry ,Red blood cell distribution width ,medicine.disease ,Sudden death ,Uremia ,Nephrology ,Diabetes mellitus ,Internal medicine ,Heart failure ,medicine ,Cardiology ,Endothelial dysfunction ,business ,Kidney disease - Published
- 2012
49. Prevalence of latex allergy in a population of patients diagnosed with myelomeningocele
- Author
-
Santiago A Portillo, Fernando A Frangi, María C Cortines, Claudio A S Parisi, Julio Busaniche, Francisco de Badiola, and Natalia Petriz
- Subjects
Male ,medicine.medical_specialty ,Allergy ,Pediatrics ,Latex Hypersensitivity ,Meningomyelocele ,Adolescent ,Latex ,Cross-sectional study ,Population ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Epidemiology ,Prevalence ,Medicine ,Humans ,Risk factor ,education ,Child ,Skin Tests ,education.field_of_study ,business.industry ,Immunoglobulin E ,medicine.disease ,Surgery ,Cross-Sectional Studies ,030228 respiratory system ,Latex allergy ,Pediatrics, Perinatology and Child Health ,030211 gastroenterology & hepatology ,business ,Anaphylaxis - Abstract
Latex allergy is one of the main reasons of anaphylaxis in the operating room. The prevalence of this condition is higher among patients with myelomeningocele. Epidemiological data obtained from Argentine patients is scarce.To estimate the prevalence of latex sensitivity and latex allergy in a population of patients with myelomeningocele and to describe associated risk factors.Descriptive, cross-sectional, observational study. Family and personal history of allergy, number of surgeries, history of symptoms caused by having been in contact with latex or cross-reactive foods, eosinophil count, measurement of total immunoglobulin E and specific immunoglobulin E levels by means of skin and serologic testing for latex, aeroallergens and cross-reactive fruit.Eighty-two patients diagnosed with myelomeningocele were assessed: 41 were males and their average age was 15.3 ± 7.66 years old. Out of all patients, two did not complete skin and serologic testing. Among the remaining 80 patients, 16 (19.51%) had latex allergy, 46 (57.5%) were not allergic, and 18 (22%) showed sensitivity but not allergy. Having undergone more than five surgeries was a risk factor associated with latex allergy (p= 0.035). No significant association was observed with the remaining outcome measures.According to this study, the prevalence of latex allergy in this population of patients is 19.51% and the most important risk factor for this condition is a history of having undergone more than five surgeries.La alergia al látex se encuentra dentro de las primeras causas de anafilaxia en el quirófano. La prevalencia de esta enfermedad es más elevada en pacientes con mielomenigocele. Existen escasos datos epidemiológicos en pacientes argentinos.Estimar la prevalencia de la sensibilidad y de la alergia al látex en una población de pacientes con mielomeningocele y describir los factores de riesgo asociados.Estudio descriptivo, transversal, observacional. Se analizaron los antecedentes familiares y personales de alergia, el número de procedimientos quirúrgicos, la historia de síntomas ante el contacto con látex o alimentos con reactividad cruzada, el recuento de eosinófilos, la inmunoglobulina E total y la inmunoglobulina E específica mediante pruebas serológicas y cutáneas para el látex, los aeroalérgenos y las frutas con reactividad cruzada.Se evaluaron 82 pacientes con diagnóstico de mielomeningocele, 41 del sexo masculino (50%), con edad promedio de 15,3 ± 7,66 años. Del total de los pacientes, 2 no realizaron las pruebas cutáneas y serológicas. De los 80 restantes, 16 (19,51%) presentaban alergia al látex, 46 (57,5%) no eran alérgicos y 18 (22%) fueron sensibles pero no alérgicos. Se observó que haber tenido más de 5 cirugías representaba un factor de riesgo asociado a alergia al látex (p= 0,035). No se encontró una asociación significativa con el resto de las variables evaluadas.El estudio estima que la prevalencia de alergia al látex en esta población de pacientes es de 19,51% y que el factor de riesgo más importante para el desarrollo de esta patología es el antecedente de haber sido sometido a más de 5 intervenciones.
- Published
- 2015
50. Quality Evaluation of Allergen Immunotherapy Guidelines Worldwide Using AGREE-II
- Author
-
Claudio A S Parisi, Bettina Wedi, José Antonio Ortega Martell, Jorge A. Luna-Pech, Désirée Larenas Linnemann, Maximiliano Gómez, Alla Nakonechna, Ignacio Davila-Gonzalez, Oliver Pfaar, Michael Levin, Nelson Rosario, Ludger Klimek, and Darío Antolín-Amérigo
- Subjects
Allergen immunotherapy ,medicine.medical_specialty ,business.industry ,media_common.quotation_subject ,Immunology ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Immunology and Allergy ,Quality (business) ,Agree ii ,030212 general & internal medicine ,Intensive care medicine ,business ,media_common - Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.